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Summary 
In the treatment of pre-menopausal women with oestrogen positive (ER+) 
breast cancer, tamoxifen represents a first line of adjuvant treatment with 
demonstrable benefits. Despite this, resistance is frequently acquired to 
tamoxifen with an associated poor prognosis. Breast cancer cell models have 
revealed the importance of growth factor signalling networks in sustaining 
growth of endocrine-resistant cancers and, more recently, their ability to 
promote a highly migratory and invasive phenotype, together with the 
expression of genes with pro-angiogenic ontology. The potential of endocrine-
resistant cells to elicit angiogenic responses, however, remains unknown. Real-
time PCR was used to validate results from preliminary Affymetrix-based gene 
profiling of pro-angiogenic gene expression in endocrine-sensitive MCF7wt cells 
and their endocrine resistant counterparts. The expression of pro-angiogenic 
factors in conditioned media (CM) from these cells was assessed by ELISA. 
The proliferative and migratory effects of conditioned media on vascular 
endothelial cells (HUVEC and HECV cells), was determined by MTS cell 
proliferation assay, wound closure assays and Matrigel tubule formation assays. 
Changes in endothelial cell migration following co-culture with endocrine-
resistant cells were examined using Boyden-chamber chemotaxis assays. 
Growth factor signalling and migration pathway activation in endothelial cells in 
response to CM was determined by Western blotting. TamR cells were found to 
express high levels of IL-8 and VEGF at an mRNA level compared with 
expression in MCF7wt cells. High levels of VEGF protein were also confirmed in 
the conditioned media from TamR cells versus their endocrine-sensitive 
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counterparts. TamR conditioned media promoted in vivo and ex vivo endothelial 
cell proliferation, as well as in vitro endothelial cell migration and the formation 
of tubules to a greater extent than that seen in MCF7wt CM treated cells. TamR 
conditioned media was found to stimulate VEGFR2 phosphorylation and 
downstream activation of MAPK and Akt in endothelial cells compared to 
MCF7wt CM. Pharmacological inhibition of VEGFR2 activity in endothelial cells 
suppressed TamR-induced endothelial cell proliferation and VEGFR 
phosphorylation. Further pharmacological manipulation of Src kinase in TamR 
cells revealed a Src kinase dependent mechanism of VEGF production in these 
cells. In addition, in vivo examination of TamR xenografts illustrated higher 
presence of endothelial cells in these tissues than in MCF7wt xenografts. These 
data suggest acquired tamoxifen resistance is accompanied by development of 
a Src kinase-dependant pro-angiogenic phenotype which, if recapitulated in 
vivo, may promote tumour progression. Therapeutic targeting of Src signalling 
may prove beneficial in such cases. 
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Chapter 1: General Introduction 
1.1 Breast Cancer 
Breast cancer represents a heterogeneous group of diseases of the breast 
characterised by an uncontrolled proliferation of cells that line either the ducts or 
lobes. 
Breast cancer is currently the most common malignancy in women worldwide 
and is the leading cause of cancer-related mortality (Benson et al., 2009; 
Clarke, 1996; Gabriel et al., 2005). Globally, more than 1.2 million cases are 
diagnosed every year (representing 10–12% of the female population) with 
around 500,000 deaths attributable to the disease. In the UK alone, over 45,000 
new cases are diagnosed annually which constitutes a 50% increased 
incidence of breast cancer over the last 25 years (Office for National Statistics, 
2008). Despite a higher prevalence of breast cancer in industrialised than in 
non-industrialised countries, incidence rates are also steadily increasing in less 
affluent societies (Porter, 2008). Increased rates of disease diagnosis have 
been attributed to earlier detection as a result of screening programs coupled 
with better and more varied treatments, and thus, decreased mortality (D. 
Maxwell Parkin et al., 2006).  
1.1.1 Risk Factors 
A number of factors are described that contribute to an increased risk of 
developing breast cancer. These are varied and include diet, obesity, 
reproductive history and socioeconomic status. However, the most prominent 
are age and gender. Incidence rates rise rapidly every 10 years and especially 
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between the ages of 35 and 39 years, slowing around 50 years, corresponding 
to the average onset of menopause, and subsequently increase to a maximum 
after 80 years (Figure 1.1) (Anderson et al., 2005; Benson et al., 2009; Cancer 
Research UK, 2009a). The incidence of hormone-receptor-negative (HR-) 
tumours increases rapidly until age 50 years and then levels-off or decreases. 
In contrast, the incidence of hormone-receptor-positive tumours (HR+) is similar 
up to the age of 50 years, but then continues to climb at a slower pace. Thus 
HR- tumours tend to occur earlier in life and HR+ tumours are more common in 
older women. The peak ages of onset for these two tumour phenotypes are 50 
and 70 years of age, respectively, and they seem to have different underlying 
causes and pathobiology (Benson et al., 2009).  
 
Figure 1.1 Breast Cancer Incidence Rates per 100,000 Women. Adapted from 
(Cancer Research UK, 2012) 
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Some dietary factors are implicated in the development of breast cancer 
including alcohol consumption which has been proposed to increase oestrogen 
exposure (Nagata et al., 1997). Foods that are high in fat may also contribute to 
breast cancer by also elevating circulating oestrogen (Boyd et al., 1993).  
Exposure to ionising radiation is associated with a higher incidence rate of 
breast cancer development. In women who survived the atomic blasts in 
Nagasaki and Hiroshima during the Second World War the incidence rate was 
very high (Land, 1995). In addition, women who had received mantle radiation 
therapy in order to treat Hodgkin’s lymphoma also had a greater incidence of 
developing breast cancer (Bhatia et al., 1996). In both cases, the progression to 
breast cancer was attributed to the exposure to radiation during adolescence 
when breast tissue is actively developing (Martin et al., 2000).  
1.1.1.1 Genetic Factors 
Two genes, BRCA1 and BRCA2, which function as tumour suppressors have 
become recognised as powerful predictors for risk of developing breast cancer. 
BRCA1 has been suggested to play a role in a diverse set of cell functions 
including transcription, cell cycle control and DNA damage repair. It has been 
shown to associate with RNA polymerase II and to enhance the transactivation 
of p53 (Anderson et al., 1998). The function of BRCA2 seems less well defined 
although mutations in the gene are associated with widespread chromosomal 
rearrangements. In addition, the absence of the gene results in shortening and 
dysfunction of telomeres (Min et al., 2011).  
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Women who have an abnormal BRCA1 or BRCA2 gene have up to a 60% risk 
of developing breast cancer; increased risk of developing ovarian cancer is 
about 55% for women with BRCA1 mutations and about 25% for women with 
BRCA2 mutations (Breastcancer.org, 2010).  
1.1.1.2 Racial Differences 
There are pronounced racial differences in the incidence and mortality of breast 
cancer (Byrne et al., 1995). In younger patients breast cancer incidence rates 
are higher in African-American women, whereas rates are greater in their 
Caucasian counterparts at 50 years of age and older. Black women have a 
higher proportion of oestrogen receptor-negative tumours than white women do 
and are therefore less likely to receive endocrine treatment (Jatoi et al., 2005). 
Within the Ashkenazi Jewish population, 2.0% – 2.5% of women carry mutant 
BRCA1 and BRCA2 genes and 12% of breast cancers can be attributed to 
mutations in these genes which has led to increased screening in these 
populations (Warner et al., 1999).  
1.1.1.3 Oestrogen Exposure 
One of the most significant risk factors for breast cancer is the exposure to 
endogenous and exogenous oestrogens over one’s lifetime, given the role of 
the ER as a promoter of breast tumour development and progression. Thus, 
early menarche (<12 years vs. 16 years) and late menopause (>55 years vs. 
<45 years) are associated with a relative risk increase of about 20% (Hankinson 
et al., 2004). Use of hormone replacement therapy (HRT) with exogenous 
oestrogen in postmenstrual women has an associated increased risk of 
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developing breast cancer reportedly in the region of 35% after 10 years of use, 
although cancers developing in these women tend to have more favourable 
prognosis (Colditz, 2005). For this reason it is contra-indicated in survivors of 
breast cancer as it can double the risk of relapse (Holmberg et al., 2008).  
1.1.2 Breast Anatomy  
The breasts are mammary glands whose primary function in females is to 
provide nutrition to infants. They are predominantly made up of adipose and 
glandular tissue with connective tissue throughout (Ramsay et al., 2005). They 
are located bilaterally within the subcutaneous layer of the thoracic wall. In 
terms of anatomy they may be divided into three main sections; the mammary 
gland itself, the mammary papilla and the areola. The mammary gland (Figure 
1.2) consists of lobes, of which there are usually between 15 to 25 arranged in a 
radial pattern around the areola. The lobes themselves are divided up into 
lobules which are the functional units of milk production. The lactiferous duct 
describes the principal duct of each lobe which drains into the mammary papilla 
(Drake, 2005).  
Cancers of the breast are most commonly found to originate in either the 
lobules or in the ducts. The area between the lobes is primarily made up of 
adipose and connective tissue (Drake, 2005). Fascicles of connective tissue, 
known as Cooper’s ligaments, run anteroposteriorly from the clavicle, 
permeating the lobes and lobules and giving structure and support to the breast 
tissue. Breast cancer can affect these ligaments and cause them to pull on the 
skin causing a characteristic dimpling of the surface of the breast (Figure 1.3). 
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Figure 1.2 Tissue anatomy of right breast. Absence of skin and subcutaneous layer 
allows observation of the lobes, frontal ducts and lactiferous tubules. Image adapted 
from Gray’s 20th Edition.  
 
Figure 1.3 Skin Dimpling as a Result of Carcinoma Proximal to Coopers 
Ligaments. Image freely available under Creative Commons, no rights reserved. 
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1.1.3 Breast Cancer Subtypes, Classifications and Staging 
As mentioned previously, breast cancer is a heterogeneous disease and as a 
consequence, no one treatment option is sufficient for all breast cancers. Thus 
the treatment must be adapted to match the clinical tumour subtype. The 
majority of breast cancers arise from epithelial tissue (carcinomas) or from the 
glandular epithelial tissue itself (adenocarcinoma). More rarely, cancers of the 
connective tissue of the breast may develop which are referred to as 
angiosarcomas (Vorburger et al., 2005). Classification systems for breast 
cancers are commonly used to describe properties found during diagnosis and 
form a method of devising treatment regimens based on these properties. 
These methods of classification also play an important role as different breast 
cancer subtypes have different prognoses. Thorough classification often 
involves documenting the tumour histopathology, grade, stage, presence of 
specific receptors and mutations in known DNA markers. Classification of 
tumours is now based on how far the tumour cells have differentiated from their 
tissue of origin and organises them into the following categories.  
1.1.3.1 Carcinoma in situ 
Ductal Carcinoma in situ (DCIS) is the most common form of non-invasive 
breast cancer, representing 20% of diagnosed breast cancers (Sanaz A, 2011). 
Ductal refers to its origin within the breast where, although it is hyperplastic, it is 
localised to the duct and does not invade into the surrounding tissue, hence in 
situ (Allred, 2010). Lobular Carcinoma in situ behaves in a similar fashion in that 
the cells remain confined within the affected lobule.  
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1.1.3.2 Inflammatory Breast Cancer 
Frequently, presentations of localised breast inflammation are subsequently 
diagnosed as an aggressive form of breast cancer termed inflammatory breast 
cancer. These cancers account for 2.5% of all diagnosed and are characterised 
by high incidence of metastases, both local and distant, rapid progression and 
low overall survival (Robertson et al., 2010). Other forms of breast cancer are 
rarer, accounting for less than 1% of incidences and include male breast 
cancers and tumours of the nipple.  
1.1.3.3 Invasive Ductal or Lobular Carcinoma 
The majority of breast cancers at diagnosis are either of invasive ductal 
carcinoma (IDC) or invasive lobular carcinoma (ILC) type. These cancers are 
not confined to their site of origin and have invaded into the surrounding stroma. 
IDC is the most common type of breast cancer with an incidence rate of about 
55% (Eheman et al., 2009), whereas ILC only accounts for 8 – 15% (Pointon et 
al., 1999).  
1.1.3.4 Clinical Classification 
There are a number of dominant clinical subtypes of invasive ductal breast 
cancers, characterised primarily by the expression of specific receptors. The 
presence of these receptors not only defines the subtype but has a significant 
bearing on which drug treatments are likely to prove effective. In breast cancer, 
as in others such as ovarian and prostate cancer, they can respond to the 
action of various hormones and deprivation of this signalling can reduce the 
growth of these tumours. In breast cancer, hormone status usually refers to the 
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expression of oestrogen-receptor alpha (ERα) and the progesterone receptor 
(PR). Approximately 60 – 70% of breast cancers present as ER+ and are 
associated with an overall better prognosis, therefore the presence or absence 
of detectable ER is an important prognostic indicator. In addition, HER2 status 
is a widely used marker in breast cancer classification. Outlined below (Table 
1.1) are the major clinical subtypes and their associated five year overall and 
disease free survival percentages (Onitilo et al., 2009).  
Subtype Overall Survival Disease-free Survival 
ER/PR+, HER2+ 88.7% 83.2% 
ER/PR+, HER2- 90.3% 86.8% 
ER/PR-, HER2+ 78.8% 66.0% 
ER/PR-, HER2- 79.0% 73.5% 
Table 1.1 Five year overall and disease-free survival by tumour subtype. ER = 
oestrogen receptor, HER2 = human epidermal growth factor receptor 2, PR = 
progesterone receptor, + = positive, - = negative. Adapted from (Onitilo et al., 2009) 
 
In addition to these three main breast cancer markers, the nuclear antigen, Ki-
67 is being trialled as a potential fourth marker. This protein is expressed during 
proliferation but not while a cell is in G0. Tumours which demonstrate high Ki-67 
result in higher disease reoccurrence and shorter survival times and so it has 
become widely reported as possessing good prognostic value (Yerushalmi et 
al., 2010). In terms of predicting response, some studies have shown it may 
have value in predicting benefit of certain chemotherapy regimens in some ER+ 
breast cancers (Penault-Llorca et al., 2009) as well as in ER- tumours, although 
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this may be as a result of increased proliferation in these tumours (Jones et al., 
2010).  
1.1.3.5 Molecular Markers 
A further level of complexity regarding classification of breast cancer is 
suggested from studies that have determined the genetic profile of breast 
cancer cell lines and tissue. Initial approaches (e.g. that described by Charles 
M. Perou (2000)), using array analysis of tumour gene signatures, sought to 
classify tumours based on the clustering pattern of gene expression with the 
subsequent identification of several molecular subtypes of breast cancer (Perou 
et al., 2000). These markers include HER2, Ki-67, c-myc, p53 and E-cadherin. 
Following on from this work, five dominant molecular subtypes have been 
identified.  
The luminal A and luminal B subtypes are both ER positive and share molecular 
characteristics of the luminal cells that surround the mammary ducts. However, 
whereas luminal A is associated with good prognosis, luminal B is associated 
with a much poorer prognosis. The explanation behind why luminal B cancers 
have a worse prognosis when both they and luminal A cancers are ER+ has 
been attributed to; the relative low expression of PR and the fact they are highly 
proliferative (Creighton, 2012). HER2 sub-type tumours, those that overexpress 
the HER2 receptor, occur as 25% of breast cancer tumours and are associated 
with a more aggressive phenotype, and a poor prognosis (Hicks et al., 2008). 
Tumours of the basal subtype originate from the basal layer of the breast 
epithelium but these cells are generally ER and PR negative and do not 
11 
 
overexpress HER2 (these are often termed triple negative). Finally, the normal-
like subtype expresses increased levels of basal-genes but reduced expression 
of luminal associated genes (Sørlie et al., 2001; Sørlie et al., 2003). The 
normal-like subtype accounts for 6-10% of breast cancers, they tend to be small 
in diameter and be associated with a good prognosis (Perou et al., 2000).  
A novel approach to molecular classification of tumours was published this May 
in which Curtis et al. proposed that by assessing single-nucleotide 
polymorphisms, in addition to copy number aberrations and copy number 
variants, that genetic profiles of breast cancers resolve into ten potential 
“integration clusters” some of which e.g. IntClust5 are associated with a poor 
prognosis clinically (Curtis et al., 2012).  
Although currently, the classification of tumours based on molecular subtypes is 
of greatest use in research and has not been implemented into standard 
medical practice, it represents an important area of study in the context of 
personalised medicine.  
1.1.3.6 Stage and Grading for Prognostic Information 
Histopathology classifies tumours based on observations made by a technician 
when examining biopsy material taken from the patient in addition to information 
from the physical exam and imaging of the breast. Methods for analysing these 
observations vary between institutions; however, one commonly used system is 
the TNM Classification of Malignant Tumours. TNM stands for ‘Tumour, Node 
and Metastasis’ where Tumour refers to the size and location of tumour, Node 
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describes if there has been any involvement of lymph nodes and Metastasis 
refers to the presence or absence of secondary tumour sites. 
Tumour size is an important factor as generally the smaller the tumour is on 
initial examination, the better the prognosis for the patient. The score assigned 
to “T” can also describe spread of the tumour towards the skin or the chest wall.  
Lymph node involvement, donated by the letter “N” is concerned with the 
presence or absence of relatively large numbers of cancer cells being detected 
in the lymph nodes (~200 cells). However, as technology and our understanding 
of tumour progression evolve, we possess the capability to detect isolated 
tumour cells using immunohistochemistry and PCR techniques. 
Metastasis, designated “M”, uses information from imaging studies to determine 
the presence of secondary tumour sites in the blood, bone marrow or distant 
organs. For each of the letters T, N and M a number is assigned which donates 
severity and when taken together can help direct treatment and predict 
prognosis (Cancer Research UK, 2009b; Güth et al., 2007). Using the 
Nottingham Criteria each feature is assigned a score between 1 and 3 (with 1 
being the best and 3 being the worst) then combining these values to give a 
total score (Bloom et al., 1957; Elston et al., 1991). Depending on the score, 
tumours are assigned into one of three grades; Score 3-5 Low Grade (I), Score 
6-7 Intermediate Grade (II), or Score 8-9 High Grade (III). If a tumour presents 
as well differentiated, low grade tumour it will have a better prognosis than 
those that are poorly differentiated and therefore high grade (Balslev et al., 
1994).   
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1.1.4 Current Treatments in Breast Cancer 
First-line treatment for many forms of breast cancer is surgical excision of the 
primary tumour (or more radically, mastectomy) followed by radiation therapy to 
remove secondary tumour sites and stray cancer cells. In women with slowly 
progressive ER+ metastatic breast cancer, endocrine therapy is given rather 
than chemotherapy to target remaining cells. This recommendation is based 
upon reduced toxicity of endocrine treatment, and generally longer durations of 
response as compared to cytotoxic chemotherapy, with no difference in overall 
survival (Wilcken et al., 2003). Occasionally, neoadjuvant therapy is carried out 
to reduce the size of tumours and increase the success of surgical intervention.  
1.1.4.1 HER2+ breast cancer 
The human epidermal growth factor family of receptors consists of four 
members, HER1 (EGFR2), HER2, HER3 and HER4. They are bound by a 
variety of growth factors which are outlined below (Figure 1.4) with the 
consequence of receptor activation being an array of functional and cell survival 
related processes (Hynes et al., 2005). The HER2 gene is known to be 
amplified in around 25% of invasive breast cancers leading to significant 
overexpression of the HER2 receptor on these cells where it is associated with 
poor outcomes. (Slamon et al., 1987). In light of this, a number of approaches to 
target HER2 in the clinic have been developed. The humanised monoclonal 
antibody trastuzumab (Herceptin) binds to the extracellular domain of HER2 
and results in reduced downstream activation leading to cell cycle arrest. In a 
clinical setting, trastuzumab has anti-tumour activity as a monotherapy and in 
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conjunction with chemotherapeutics (Inoue et al., 2010; Marty et al., 2005). 
Despite its success, resistance to trastuzumab therapy will commonly develop 
after a year of treatment, with a number of mechanisms suggested to underlie 
resistance including cross talk between HER2 and other HER family members 
and increased signalling through PI3K and Src kinase dependent pathways 
(Berns et al., 2007; Muthuswamy, 2011; Nahta et al., 2005).  
In addition to therapy with trastuzumab, the dual HER2 and EGFR inhibitor, 
lapatinib (Tykerb), has demonstrated potent anti-tumour effects in both 
preclinical (Rusnak et al., 2001) and clinical studies (Baselga et al., 2012; 
Konecny et al., 2006) as a monotherapy and in combination therapies. It has 
shown significant improvement in time to progression when added to treatment 
regimens with chemotherapeutic agents such as capecitabine (Cameron et al., 
2008). Novel therapies for HER2- overexpressing breast cancers include 
trastuzumab-DM1 (T-DM1), which is a conjugate of the antibody trastuzumab to 
a cytotoxic, mertansine. In preclinical studies it has been shown to have potent 
anti-tumour effect on HER2 overexpressing cells as well as trastuzumab and 
lapatinib resistant models (Junttila et al., 2011).  
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Figure 1.4 EGFR ligands and their receptors. As shown here, no ligand directly 
binds HER2. The other receptors form homo- and heterodimers on ligand binding and 
HER2 can heterodimerise with any of these. This results in autophosphorylation of 
tyrosine residues in the cytoplasmic domain of the receptor, leading to initiation of 
downstream signalling. Adapted from (Marmor et al., 2004) 
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1.1.4.2 Triple Negative Breast Cancer 
Tumours that do not express both the oestrogen and progesterone receptors 
and also have low or non-amplified expression of HER2 are known as triple-
negative breast cancers. Due to the absence of these proteins, these cancers 
are resistant to most targeted therapies and are frequently associated with a 
very aggressive phenotype and a poor prognosis (Dent et al., 2007). Due to a 
lack of molecular targets current treatment options include chemotherapeutics 
such as the DNA-targeting cytotoxic cisplatin and PARP inhibitors. More 
recently, EGFR inhibition is being investigated as a potential therapeutic option 
with some success (Naoto T. Ueno, 2011; O'Shaughnessy et al., 2011; Silver et 
al., 2010). 
1.1.4.3 Chemotherapy 
There are several different chemotherapy regimens that are used in the clinic at 
the moment. Most of which are combination therapies typically employing an 
anthracycline agent such as doxorubicin and a taxane such as docetaxel (von 
Minckwitz, 2007). Although this is widely used, there remain challenges with 
increased toxicity in combining agents. The addition of the nitrogen mustard 
cyclophosphamide was introduced after a successful phase 3 trial carried out by 
the Breast Cancer International Research Group in 1997 that referred to the 
three drug combination as TAC (Taxane Anthracycline Cyclophosphamide). 
The trial illustrated that the TAC improved disease free-survival time when 
compared to the previous chemotherapy regimen (FAC) consisting of 
anthracycline and cyclophosphamide with fluorouracil replacing taxane use 
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(Nabholtz et al., 2002). Further study has confirmed that TAC does provide a 
better therapeutic advantage over use of FAC; however, this comes with 
increased toxicity. Incidence of neutropenia and congestive heart failure is 
higher in patients on the TAC regimen than on FAC. As a result of the lack of 
tissue specificity and high incidence of toxicity, the development of targeted 
therapies in the treatment of breast cancer has become a major research goal. 
1.1.4.4 Anti-oestrogen Therapy 
Oestrogens are a class of steroid hormone that play a vital role in the regulation 
of the female oestrous cycle in humans and are the primary female sex 
hormone. These hormones function in the regulation of ovulation, pregnancy 
and lactation. In addition, they also play a role in maintaining proper function of 
the immune system, CNS, bone and the cardiovascular system, both in males 
and females. There are three family members of oestrogens, oestrone (E1), 
oestradiol (E2) and oestriol (E3) with the primary functional oestrogen in pre-
menopausal women being oestradiol.  
Oestrogens bind the oestrogen receptor (ER) which has two isoforms alpha 
(ERα) and beta (ERβ) (Katzenellenbogen et al., 2000). These receptors 
function as transcription factors and so regulate the expression of a variety of 
genes.  
The two oestrogen receptor subtypes have different localisations with ERα and 
ERβ being expressed predominantly by cells in both male and female 
reproductive tracts, ERα has also been detected in the female breast, 
endometrium and hypothalamus whereas ERβ has been  detected in several of 
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the major organs, endothelial cells and the intestine of both males and females 
(Couse et al., 1997). As the oestrogen receptors are steroidal hormone 
receptors, they are not confined to the cell membrane and can bind oestrogen 
in the cytosol. On activation by oestrogen (Figure 1.5) this receptor forms a 
dimer that can be either a homodimer (ERαα/ERββ) or a heterodimer (ERαβ). 
On binding to oestrogens, the receptor translocates into the nucleus where it 
dimerises and can then bind to specialised promoter regions on DNA, termed 
oestrogen response elements, the activation of which leads to the transcription 
of gene sequences for a plethora of proteins. In addition to binding ER in the 
cytosol and inducing effects through transcription of genes, oestrogen can also 
bind ER in the cell membrane and induce signal transduction through second 
messenger systems including MAPK, PI3K, AKT, cAMP and through 
intracellular calcium changes (Klinge et al., 2005; Marino et al., 1998; Morley et 
al., 1992).  
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Figure 1.5 Genomic and non-genomic activity of oestrogen receptor binding.  
In the absence of oestradiol, ER remains complexed to chaperone proteins such as 
HSP90. Binding of E2 results in receptor phosphorylation followed by dimerisation 
before the receptor translocates to the nucleus. Here it binds to the oestrogen 
response elements of oestrogen regulated genes and recruits co-repressors and co-
activators of the gene which can increase or decrease gene expression. 
Phosphorylation of membrane bound ER at Y357 causes complex formation of the ER 
with G proteins and non-receptor tyrosine kinases such as Src and PI3K. Resulting 
signalling through MAPK and Akt leads to oestrogenic effects such as proliferation and 
cell survival.  
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Ultimately, the ability of E2 to promote the growth of ER+ breast cancers 
creates the therapeutic option to antagonise ER-E2 interaction for breast 
tumours that express the receptor. Endocrine therapy is applied in two ways; 
ablative therapy to remove the source of the oestrogen and additive therapy to 
act upon the cancer itself to prevent the proliferative action of oestrogen, 
primarily through antagonising the oestrogen receptor. 
Ablation of ovarian function is carried out by bilateral oophorectomy, hormone 
manipulation or by radiation therapy directed at the ovaries; however this 
treatment is only suitable for pre-menopausal women. In post-menopausal 
women the majority of oestrogen is synthesised by the adrenal glands. In 
addition, oestrogen may be synthesised by enzyme conversion of circulating 
hormones, such as testosterone and androstendione into oestrogen and 
oestrone. The enzyme aromatase is responsible for this reaction and therefore 
presents a further target in the manipulation of oestrogen synthesis (Macedo et 
al., 2009). The three main classes of endocrine agents that are used in breast 
cancer therapy are summarised in Table 1.2.  
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Class Mechanism of Action Example 
Selective Oestrogen 
Receptor Modulator 
Binds to ER and has a 
mixed 
agonist/antagonist effect 
Raloxifene, tamoxifen 
Selective Oestrogen 
Receptor Modulator 
Binds to ER with a pure 
antagonistic effect 
Fulvestrant 
Aromatase Inhibitor Irreversibly bind 
aromatase enzymes 
(Steroidal) or reversibly 
compete for enzyme 
(Non-steroidal) 
Exemestane (Steroidal), 
Anastrozole (Non-
Steroidal) 
Table 1.2 Classes of anti-oestrogen used in ER+ breast cancer therapy. 
1.1.4.4.1 Selective Oestrogen Receptor Modulators 
Blockade of the ER receptor in ER positive tumours elicits a dramatic response 
in restricting growth of primary tumours as well as those that have metastasised 
(Lønning, 2004; O. Abe, 2005). Tamoxifen was initially developed as a novel 
contraceptive candidate (Jordan, 2003) and it was not until the mid-1970s that 
development began in earnest of tamoxifen as an adjuvant treatment for ER+ 
breast cancer.  
The action of tamoxifen differs depending on the tissue on which it is acting. In 
breast tissue, it acts as an ER antagonist resulting in inhibition of oestrogen-
dependent growth. In contrast, the action of tamoxifen in other tissues, such as 
the endometrium, is one of an ER agonist, with resultant stimulation of cellular 
proliferation hence tamoxifen is dubbed a “selective oestrogen receptor 
modulator” (SERM). These tissue-specific properties are thought to be as a 
result of coregulatory proteins expressed differently by specific tissue types. 
These coregulators may be co-activators which increase transcription of specific 
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genes regulated by oestrogen response elements or co-repressors which 
suppress expression (Graham et al., 2000). There is a small increase in risk of 
developing endometrial cancer with tamoxifen (Fisher et al., 1994), however in 
many cases the benefits outweigh the risks. As the target of tamoxifen is the 
ER, tumours that are ER negative do not respond well to treatment, however, 
even those that are weakly ER positive (<1% of ER+ breast cancers) still show 
substantial response (Early Breast Cancer Trialists' Collaborative, 2011; 
Qureshi et al., 2010).  
Tamoxifen is metabolised in the liver by enzymes CYP2D6 and others to its 
active metabolites 4-hydroxytamoxifen (Figure.1.6) and N-desmethyl-4-
hydroxytamoxifen (endoxifen). After binding to the oestrogen receptor, the 
nuclear complex still binds to oestrogen response elements on DNA. This way, 
tamoxifen and its metabolites not only competitively inhibit the binding of 
oestrogen but recruit co-repressor proteins including nuclear receptor co-
repressor 1 and 2, to further inhibit typical oestrogenic action (Hoskins et al., 
2009; Shang et al., 2000).  
Treatment with tamoxifen remains a popular treatment option for women who 
have significant ovarian oestrogen production. Typical treatment regimens last 
for five years with studies showing that reduced mortality rates in this treatment 
group when compared to patients that have not received adjuvant tamoxifen, 
last well beyond 10 years from the beginning of treatment (Early Breast Cancer 
Trialists' Collaborative, 2011).  
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Tamoxifen 
4-hydroxy-tamoxifen 
 
 
Figure 1.6 Structures of the anti-oestrogen tamoxifen in comparison to its more 
active metabolite 4-hydroxytamoxifen. Adapted from (Osborne et al., 2004) 
 
 
24 
 
1.1.4.4.2 Selective Oestrogen Receptor Downregulators 
The unwanted agonistic effects of tamoxifen on uterine tissues created a 
necessity for anti-oestrogen therapies that lacked these potentially problematic 
effects (Fornander et al., 1993). Subsequently, the “pure” anti-oestrogen 
fulvestrant (Wakeling et al., 1991) was developed. Fulvestrant represents a 
class of anti-oestrogens known as ‘SERDs’ (selective oestrogen receptor 
downregulators), so termed due to their ability to bind to, and promote the 
degradation of, the oestrogen receptor (Howell, 2002). 
In preclinical testing, fulvestrant showed: a higher affinity for the ER than 
tamoxifen, no oestrogenic activity in the uterus and suppression of tumour 
growth in mice for a longer period than tamoxifen (Wakeling et al., 1991). A 
further advantage of this agent was that it appeared to be effective in ER+ 
breast cancer cells that had acquired resistance to tamoxifen (Coopman et al., 
1994). In the clinic, fulvestrant resulted in reduced detectable markers of cell 
cycle proliferation including pS2 and Ki-67 (DeFriend et al., 1994) and, in 
contrast to tamoxifen, no evidence was seen of ovarian hyperstimulation or 
elevation in endometrial thickness (Thomas et al., 1994). Current trials are 
focusing on the use of fulvestrant as a monotherapy and in conjunction with 
other targeted therapies in postmenopausal women with ER positive breast 
cancer. Initial data support a role for fulvestrant in combination with anastrozole 
and gefitinib (Massarweh et al., 2011; Oakman et al., 2011; Pritchard et al., 
2010).  
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1.1.4.4.3 Aromatase Inhibitors 
In premenopausal women, the ovaries are the main source of oestrogen 
production. In postmenopausal women, however, oestrogen production is more 
abundant in other tissues including breast and adipose tissue (Nelson et al., 
2001). These tissues contain the aromatase enzyme which is responsible for 
the conversion of androgens to oestrogens. Thus, in postmenopausal women 
the aromatase enzyme represents a potential therapeutic target through which 
the oestrogenic environment of the tumour can be perturbed which may lead to 
suppression in tumour growth.  
Development of aromatase-inhibiting compounds commenced in the early 
1980s with the discovery of aminoglutethimide. However the poor specificity for 
aromatase of this compound brought about the need for more specifically-
targeted drugs (MacNeill et al., 1992). The second generation aromatase 
inhibitors (AIs) included compounds such as formestane; however these 
compounds did not block aromatase action sufficiently to produce a therapeutic 
benefit. The third and currently used generation of AIs includes the compounds 
anastrozole and exemestane which have both high selectivity and potency in 
inhibiting aromatase (Howell A, 2005). These third generation compounds can 
be further subdivided into steroidal and non-steroidal aromatase inhibitors. 
Steroidal AIs such as exemestane irreversibly bind aromatase which results in 
its degradation. Non-steroidal AIs such as anastrozole and letrozole reversibly 
bind aromatase (Geisler, 2011). At the moment there is little evidence regarding 
which aromatase inhibitor is best for any specific breast cancer subtype 
(Schneider et al., 2011). Results from clinical trials using these compounds as 
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monotherapy or as a second line treatment after failure on tamoxifen, have 
shown they provide clinical benefit and seem to be superior to use of tamoxifen 
monotherapy in post-menopausal women who have localised breast tumours 
that are ER+ (Baum et al., 2002; Goss et al., 2003).  
1.1.4.4.4 Contrasting Tamoxifen and Aromatase Inhibitors in the 
Treatment of Breast Cancer in Postmenopausal Women 
Despite both tamoxifen and anastrozole being indicated for use in hormone 
positive breast cancer in either post-menopausal women or those that have 
received ovarian ablation therapy, the results of the now famous ATAC trail 
cemented the preferential use of anastrozole over tamoxifen. This was as a 
result of the observed increase in disease free survival, time-to-reoccurrence 
and reduced incidence of distant metastasis development and contralateral 
breast cancers with the use of anastrozole as well as a documented reduction 
in the reporting of side-effects (Howell A, 2005). Similar data has been collected 
by the TEAM trial examining tamoxifen versus exemestane with increases in 
disease free survival when exemestane was combined with tamoxifen or when 
exemestane was used as a monotherapy (van de Velde et al., 2011). In pre-
menopausal women, and in those with functioning ovaries that produce 
oestrogen, tamoxifen is still indicated as a first line adjuvant.  
1.2 Endocrine Resistance 
Despite the clinical effectiveness of endocrine agents in the treatment of ER+ 
breast cancer, the success of these agents is limited by the phenomenon of 
resistance. About 60% of ER+ breast cancer patients who initially respond to 
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tamoxifen will require further therapy as a result of recurrence or metastasis. 
Around a third of early breast cancers and almost all advanced breast cancers, 
initially responsive to tamoxifen, will relapse (acquired resistance) (Horobin et 
al., 1991; Ring et al., 2004) whilst a significant minority of tumours will fail to 
respond to endocrine agents despite being hormone receptor positive (de novo 
resistance). A number of important mechanisms have been suggested to 
underlie de novo and acquired resistance which are discussed in the following 
sections. 
1.2.1 De novo Resistance 
Intrinsic resistance to endocrine treatment in ER+ breast cancer may arise due 
to reduced expression of ERα. Additionally, reduced expression of the 
cytochrome p450 family enzyme, CYP2D6, responsible for the metabolism of 
tamoxifen into its active metabolite, 4-OH-tamoxifen may reduce the efficacy of 
tamoxifen therapy (Hoskins et al., 2009).  
1.2.2 Acquired Resistance 
In ER+ tumours that initially respond to treatment with tamoxifen, two-thirds of 
these patients will eventually relapse with anti-oestrogen resistant tumours. This 
resistance is therefore a major issue clinically. Initially, 90% of primary breast 
cancers and 50% of metastases are effectively treated by anti-oestrogens as 
demonstrated by reduced tumour volume, improved symptoms, and decreased 
circulating tumour markers. However, after a variable period progression occurs 
and is commonly accompanied by resistance to treatment (Gonzalez-Angulo 
AM, 2007) despite continued expression of ERα (Riggins et al., 2007).  
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By determining the mechanisms by which cancer cells become resistant to anti-
oestrogen therapy we can begin to develop methods of preventing its 
occurrence.  
1.2.2.1 ER 
Loss of expression or function of ERα during treatment can confer tamoxifen 
resistance, however this only occurs in a minority of cases (~15%) (Gutierrez et 
al., 2005). Many tumours retain expression of ER (both ERα and ERβ) 
indicating that it may be more common for oestrogen receptors to lose function 
possibly due to mutations in the genes that encode the receptor (Ring et al., 
2004). Mutation studies have illustrated that amino acid substitution within the 
ER can lead to normal expression of the receptor but with a loss of functionality 
in terms of 4-hydroxytamoxifen binding or the ability of the ER to mediate 
transcription of ERE regulated genes (Mahfoudi et al., 1995; Schafer et al., 
2000). However this is not a common occurrence and so does not account for 
the majority of acquired tamoxifen resistance (Karnik et al., 1994). In addition to 
genetic changes, epigenetic modifications such as CpG island hypermethylation 
of ERα can cause inactivation of ER gene transcription. The problem clinically 
therefore, is that ERα gene expression may not relate to ERα function.  
Following the discovery of a second ER receptor, ERβ, studies have shown that 
its gene expression is elevated in patients with acquired tamoxifen resistance 
compared with tamoxifen-sensitive patients (Speirs et al., 1999), suggesting 
that ERβ represents a factor for predicting poor prognosis, data which has been 
corroborated by another group who reported that expression of ERβ is 
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associated with a more aggressive tumour phenotype (Novelli et al., 2008). 
Additionally, ERβ predicted response in patients who were determined to be 
ERα- but ERβ+, illustrating that ERβ modulation of oestrogenic activity is 
sufficient to illicit a therapeutic response in the absence of ERα activity (Honma 
et al., 2008).  
In pre-menopausal women tamoxifen treatment results in an increase in the 
levels of oestrogen (Ravdin et al., 1988). Although this could hypothetically limit 
the capability of tamoxifen to bind the ER by saturating the receptor with 
oestrogen, this has not been shown to be linked with acquisition of resistance 
(Ring et al., 2004).  
1.2.2.2 Co-factors 
As oestrogen function can also be modulated by interactions with co-activators 
(such as AIB1) and co-repressors (such as SMRT) (McKenna et al., 1999), the 
alteration of these proteins in acquired tamoxifen resistance can further alter the 
outcome of receptors binding to the ERE (Smith et al., 2004). Elevated AIB1, for 
example, has been associated with a better outcome in patients who have not 
received adjuvant tamoxifen, but a poorer outcome in those who did (Osborne 
et al., 2003). It has been hypothesised that these activators function to increase 
agonistic activities of tamoxifen and acquisition of resistance (Ring et al., 2004). 
Furthermore, changes in post-translational modifications that regulate ERα 
function that affect how ER interacts with transcriptional co-regulators and other 
signalling molecules have been shown to contribute to acquired endocrine 
resistance (Musgrove et al., 2009).  
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Finally, altered expression of classical effectors of apoptosis and cell survival 
can predict a poor response to anti-oestrogen treatment, these include Bcl-2, 
p53, c-Myc and Bad (Cannings et al., 2007; Linke et al., 2006; Planas-Silva et 
al., 2007).  
1.2.2.3 Growth Factor Receptor Crosstalk 
One mechanism by which resistance to endocrine therapies has been 
suggested to develop occurs via crosstalk between growth factor signalling 
pathways and the ER. Studies investigating the relationship between ER and 
HER2 signalling have illustrated that the crosstalk between these systems plays 
a pivotal role in the development of resistance to ER targeted therapies (Arpino 
et al., 2008). Tumours that are initially responsive to tamoxifen tend to have low 
levels of HER2 and EGFR. However, on acquisition of tamoxifen resistance 
such tumours are found to have elevated levels of these receptors which can 
lead to increased EGFR/HER2 pathway activity (Gutierrez et al., 2005; Meng et 
al., 2004). In vitro studies have illustrated that tamoxifen resistant cells in culture 
express elevated EGFR and HER2 with an accompanying increase in activation 
of these receptors as well as their downstream components including MAPK 
and AKT (Nicholson et al., 2004). The correlation between this increase in 
second messenger signalling and the acquisition of tamoxifen resistance is not 
fully understood but it has been suggested that contributing factors include: 
decreased ERα expression, mediated by increased MAPK signalling; loss of 
EGFR and HER2 repression by ER activity; increased mitogenic signalling; 
inhibition of apoptosis and ligand-independent activation of the ER (Musgrove et 
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al., 2009). Additionally, overexpression of proteins like the Src family of tyrosine 
kinases in breast cancer has been associated with the acquisition of resistance. 
Src kinase forms a phosphorylation dependent signalling complex with Focal 
Adhesion Kinase (FAK) and BCAR1 that results in increased cell survival 
(Cowell et al., 2006). When overexpressed in vitro, the BCAR1 protein of this 
complex can confer tamoxifen resistance to cells and conversely deletion of the 
substrate domain of the protein confers enhanced tamoxifen sensitivity 
(Dorssers et al., 1993).  
Data from our in house cell models has revealed that acquired anti-oestrogen 
resistance is associated with the development of an aggressive phenotype with 
demonstrable increases in invasion and migration. We hypothesise that these 
alterations in behaviour are mediated by an increased level of Src kinase 
activity on acquisition of tamoxifen resistance (Hiscox et al., 2006b). These 
findings may explain why clinical observations of high Src kinase is associated 
with a poor prognosis (Morgan et al., 2009). Further studies have demonstrated 
that acquired tamoxifen resistance influences tumour cell interaction with 
neighbouring cell types. Other studies have illustrated that development of 
resistance to the anti-oestrogen fulvestrant is accompanied by an elevated 
expression of the HGF receptor c-Met in vitro (Hiscox et al., 2006a). 
Additionally, tamoxifen resistant cells have enhanced adherence to endothelial 
cells (Wadhawan, unpublished data) and increased Src kinase signalling in 
tamoxifen resistant cells can uncouple FAK activation from an adhesion 
dependent process. All these elements are important in metastasis and suggest 
that the process of acquired resistance may ultimately produce cells that have 
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an augmented capacity to influence their microenvironment. One aspect of this 
that remains to be explored is whether acquired resistance alters the angiogenic 
capacity of breast cancer cells.  
1.3 Angiogenesis 
In addition to uncontrolled growth of cells at the site of the primary tumour, 
many breast cancers can also be characterised by an increased invasiveness 
and the development of metastasis to proximal and distant sites (Suva et al., 
2009). In 70% of these cases where patients die from their cancer, metastases 
are found within bones (Coleman, 2006) and in ~15% of these there is evidence 
of central nervous system and brain metastases (Patil et al., 2007).  
Metastasis is the single most important factor affecting mortality in cancer 
patients. Over 90% of cancer-related mortality is due to metastatic disease 
rather than problems associated with primary tumour growth (Weigelt et al., 
2005). Metastasis is facilitated by an established vascular network through 
which tumour cells can migrate to distant sites resulting in the establishment of 
new tumour sites.  
A vascular network is an essential component to facilitate the supply of oxygen 
and nutrients to tissue as well as playing an important role in homeostasis and 
removal of waste. Angiogenesis is the process by which new vasculature is 
developed from pre-existing vasculature; this differs from vasculogenesis, which 
is the process by which a vascular network is spontaneously developed. 
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The process of angiogenesis can be subdivided into two categories depending 
on how the vessel development occurs. If new vasculature develops from pre-
existing endothelial cells and “sprouts” into the surrounding tissue it is referred 
to as “sprouting angiogenesis” (Adair et al., 2010). This form of vascular 
development from pre-existing vessels was the first recognised form of 
angiogenesis and its process is well characterised. Initially, growth factors that 
function in stimulating angiogenesis (angiogenic factors) activate receptors on 
endothelial cells that are present on pre-existing vasculature. These endothelial 
cells then release enzymes (proteases), the function of which is to disrupt the 
basement membrane and allow migration of endothelial cells away from the 
parent vessel (Lamalice et al., 2007) . Migrating endothelial cells proliferate in 
the extracellular matrix (ECM) towards the higher ECM concentration of 
angiogenic factors (chemotaxis) but are also drawn by haptotaxis, which causes 
cells to migrate towards an increasing concentration of immobilised ligand, 
which in the case of endothelial cell migration are the components of the ECM 
to which endothelial cell integrins bind (Giroux et al., 1999). Finally, evidence 
suggest that mechanotaxis also plays a role as fluid stress on endothelial cells 
on the surface of the inner vessel wall can stimulate migration away from the 
parent vessel (Li et al., 2005).  
In contrast, splitting, or intussusceptive angiogenesis, occurs when the capillary 
wall extends into the lumen and splits a single pre-existing vessel into two 
(Paku et al., 2011).  
34 
 
Angiogenesis is stimulated in conditions of oxygen deprivation which triggers 
induction of factors regulated by hypoxia-inducible factor-1α which in turn 
initiates production of pro-angiogenic factors that function in the formation of 
new blood vessels through a number of downstream effects, including 
proliferation and migration of vascular endothelial cells, survival of immature 
endothelial cells and induction of vascular permeability in capillaries 
(Yancopoulos et al., 2000). Examples of pro-angiogenic factors include; 
vascular endothelial growth factor (VEGF) as well as, basic fibroblast growth 
factor and transforming growth factors alpha and beta (Jain, 2003). There are 
also anti-angiogenesis factors such as angiostatin, endostatin and 
thrombospondin-1 that have an opposite effect and it is the balance of pro- and 
anti-angiogenic factors that determines the rate and progression of 
angiogenesis (Cao, 2001; Chavakis et al., 2002). Deregulation of angiogenesis 
due to an increase of pro-angiogenic factors and a reduction in the activity of 
anti-angiogenic factors leads to increased vascularisation of tumours and 
therefore increases the sustainable mass of the primary tumour as well as 
increasing the incidence of metastases, facilitated by intravasation (Loges et al., 
2009).  
1.3.1 The VEGF-VEGFR Axis and Angiogenesis 
The VEGF family of growth factors consist of six described members; VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental-derived growth factor 
(PDGF). VEGF-A describes 6 isoforms of the protein, VEGF121, VEGF145, 
VEGF165, VEGF183, VEGF189 and VEGF206. As the most abundant isoform, 
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VEGF165 is often shortened to VEGF and is referred to as such in the majority of 
literature (Harper et al., 2008). VEGF is produced by a variety of cell types 
including smooth muscle cells, cancerous cells and endothelial cells 
themselves. VEGF production is primarily stimulated under conditions of 
hypoxia wherein low oxygen concentrations inhibit the enzyme HIF prolyl-
hydroxylase (which requires oxygen as a substrate). In normoxic conditions this 
enzyme hydroxylates proline residues on the alpha subunit of the transcription 
factor hypoxia-inducible factor (HIF). In these conditions the activity of the 
enzyme leads to ubiquitiniation and degradation of HIF. When oxygen is absent, 
HIF-1α (the HIF family member primarily involved in angiogenesis) is stabilised 
and functions in the upregulation of genes that lead to an angiogenic response, 
including VEGF (Adair et al., 2010).  
VEGF elicits a response on binding to receptors present on endothelial cells in 
the vasculature as well as in the lymphatic system. Receptors for VEGF have 
also been found in cancer cells of various origins including thyroid (Vieira et al., 
2005) and indeed, breast (Schmidt et al., 2008). The presence of these 
receptors on tumour cells suggests that these cells have developed autocrine 
loops that may stimulate tumour cell growth and migration. Receptors for VEGF 
(VEGFRs) are a family of membrane tyrosine kinase receptors and are 
comprised of three family members; VEGFR-1(Flt-1), VEGFR2 (Flk-1/KDR) and 
VEGFR3 (Flt-4). VEGF mediates its effect by binding, primarily, to VEGFR1 and 
VEGFR2. VEGF has a higher affinity for VEGFR1 with a Kd of 10pM whereas 
it’s affinity for VEGFR2 receptors is lower with a Kd of approximately 75 to 
125pM (Shepro, 2006). This proves interesting as VEGFR2 is the receptor 
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through which VEGF mediates most of its proangiogenic effect, leading some to 
hypothesise that in normal conditions, VEGFR1 acts to sequester VEGF and 
prevent its binding to VEGFR2 (Kowanetz et al., 2006; Olsson et al., 2006).  
When VEGF binds VEGFR2 (Figure 1.7), the receptor undergoes dimerisation 
and oligomerisation resulting in activation of the intracellular receptor tyrosine 
kinases that phosphorylate specific tyrosine residues on the cytoplasmic 
terminals of the receptor. Since most endothelial cells express both VEGFR-1 
and -2, VEGF-A can induce homodimers of each receptor type, as well as 
VEGFR-1/VEGFR-2 heterodimers. Heterodimerisation of the soluble 
extracellular domains of VEGFR-1 and -2 has been demonstrated in vitro 
(Kendall et al., 1996). Src homology 2 (SH2) domains, such as those present on 
phospholipase C (PLC), can bind the phosphorylated tyrosine residue, and in 
the case of PLCγ, mediate the activation of a mitogen-activated protein kinase 
(MAPK) cascade which in turn, leads to proliferative and survival responses in 
endothelial cells (Takahashi et al., 2001).  
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Figure 1.7 Binding of VEGF to VEGFR2. Binding of VEGF to its receptor 
results in receptor dimerisation and stabilisation of the dimer, allowing for 
autophosphorylation and following, activation of downstream signalling 
 
 
 
VEGF
VEGF
P P
PP
PI3K
Akt/PKB
p38MAPK
Raf
MEK
MAPK
Proliferation
Migration
Cell Survival
Vascular 
Permeability
VEGFR2
38 
 
In addition, VEGFR2 activation can induce the binding of SH2 adaptor protein B 
(SHB) to the intracellular tyrosine kinase domain at phosphorylated Tyr1175. 
This causes activation of phosphoinositide 3-kinase (PI3K) which results in 
elevated phosphatidylinositol 3,4,5-triphosphate levels and activation of 
downstream Akt (Dayanir et al., 2001). Akt functions in inhibiting apoptosis as 
well as regulating production of nitric oxide (NO) through stimulation of 
endothelial nitric oxide synthase (eNOS) (He et al., 1999). The importance of 
nitric oxide in regulation of angiogenesis has only been demonstrated in the 
activity of eNOS. Removal of eNOS in knockout mice resulted in impaired 
angiogenesis (Murohara et al., 1999).  
Src kinase is a member of the Src family kinase group non-receptor tyrosine 
kinases. The term “Src family kinases” encompasses a group composed of 9 
family members; Src, Lyn, Yes, Fgr, Fyn, Lck, Hck, Blk and Frk. These 
molecules are widely reported to function in response to stimuli from growth 
factor receptor binding, including EGFR and VEGFR, as well as the activation of 
adhesion molecules that extend into the ECM (Belsches-Jablonski et al., 2001; 
Lesslie et al., 2006; Thomas et al., 1997; Twamley-Stein et al., 1993). Src family 
kinases lead to downstream activation of second messenger systems like PI3K, 
Focal adhesion kinase (FAK) and MAPK signalling cascades (Eliceiri et al., 
1999). Due to its capability to influence gene expression through Stat3, Src can 
induce increased transcription of genes that regulate angiogenesis such as 
VEGF. Certain methylation events that occur in breast cancer by PRMT1 
activity (which transiently methylates ERα at R260) cause the formation of 
cytoplasmic complexes that contain ERα in addition to Src kinase as well as 
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PI3K and FAK. Although these events occurs frequently in breast cancer, their 
outcome in terms of tumour response remains unknown (Le Romancer et al., 
2008).  
Activation of PI3K by VEGF-A is dependent on FAK (Abedi et al., 1997), an 
integral tyrosine kinase in cell migration and anchorage-dependent 
differentiation. FAK is a protein tyrosine kinase which is recruited at an early 
stage to focal adhesions (found at the cell membrane where the cytoskeleton 
interacts with proteins of the extracellular matrix) and which mediates many of 
the downstream responses. The kinase activity of FAK is activated by the Src 
after which, FAK can interact with a number of down-stream signalling proteins, 
including the adaptor protein Grb2 and the p85-subunit of IP3. Studies using 
inhibition of Src have shown it not only reduces the activity of FAK but also 
suppresses VEGF expression as well as inhibiting VEGF-stimulated 
proliferation of endothelial cells (Ali et al., 2006; Han et al., 2006; Mitra et al., 
2006). 
1.3.2 Angiogenesis in Breast Cancer 
In the clinic, microvessel density has had some support as an indicator of poor 
prognosis (Arnes et al., 2012). Women who presented with fibrocystic disease 
and who had the highest vascular density were found to have the highest risk of 
developing breast cancer (Guinebretière JM, 1994). Microvessel density, when 
found to be relatively high in premalignant lesions of the breast correlated with a 
higher risk of lesions developing into breast cancer and higher density of 
microvessels is found in more aggressive variants of DCIS (Guidi et al., 1997).  
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Deregulation of angiogenesis in breast cancer is often attributed to an alteration 
in the balance between pro-angiogenic and anti-angiogenic signalling. This 
deregulation occurs in the cancer cells themselves but can affect the 
surrounding stroma, as a result of paracrine signalling. The fine balance 
between pro- and anti-angiogenic signalling is often referred to as the 
“angiogenic switch”. In normal tissue, hypoxia sets off a cascade of events 
which results in the expression of pro-angiogenic factors that “flip the switch” 
and induce growth and migration of the endothelia. In breast cancer, factors 
known to be deregulated include VEGF, which has been shown to be 
expressed at a higher concentration in the ECM of breast cancer tumours. 
The correlation between increased VEGF expression in clinical tissue and poor 
prognosis has been illustrated (Ragaz et al., 2004) and has also been tied to 
poor tamoxifen response (Foekens et al., 2001). Expression of the main 
regulator of VEGF production, HIF-1α, has also been shown to be increased in 
clinical tissue from breast cancer (Wang et al., 1995). Other evidence indicates 
that deregulation of VEGF may not be entirely as a result of increased HIF-1α 
expression. It has been suggested that VEGF may be regulated by oestrogen 
(Ruohola et al., 1999) but this seems to contradict further studies. 
Supplementation of ovariectomised mouse xenografts with E2 increased VEGF 
mRNA significantly over unsupplemented mice (Suriano et al., 2008). Although 
an in vitro study that blocked oestrogen action using tamoxifen found that VEGF 
remained increased in their cells (Bogin et al., 2002).  
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Other factors responsible for deregulation of angiogenesis in breast cancer 
discovered in preclinical models include matrix metalloproteinases (MMP). The 
function of these enzymes is to degrade the basement membrane surrounding 
cancer cells and so they can aid the migration of cancer cells into the 
vasculature as well as aiding migration of endothelial cells towards the tumour 
site (Pellikainen et al., 2004). In breast cancer these enzymes are found to have 
an increased expression which can lead to a more invasive and metastatic 
tumour phenotype (Bartsch et al., 2003).  
Several methods have been implemented in targeting different aspects of 
angiogenic signalling. Inhibition can be carried out by: directly targeting the 
ligand (VEGF protein) or before it is translated by targeting the mRNA; by 
targeting the receptors to which it binds, the VEGFR family of receptors; or by 
inhibiting downstream signalling components of the VEGF pathway. As such 
there is little data for its efficacy in treatment of acquired resistance but there is 
pre-clinical and clinical data supporting a role for the mediators of angiogenesis, 
such as VEGF, in the biology of tumour development that may be ER regulated. 
Targeted anti-angiogenic therapy may provide increased therapeutic benefit in 
endocrine-resistant cancers or delay the onset of resistance by limiting the 
mechanisms by which resistance may occur.  
1.4 Conclusions  
 
Although many women progress well on endocrine therapy the majority 
receiving tamoxifen will eventually relapse with endocrine-resistant disease. 
This relapse is not only associated with reduced efficacy of primary anti-
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hormone treatment but also presents with a more invasive and motile 
phenotype which presents a major clinical issue. The capacity of anti-endocrine-
resistant cancers to induce angiogenesis, however, has not been explored. 
1.5 Aims 
 
We hypothesised that development of acquired endocrine resistance in breast 
cancer is associated with acquisition of a proangiogenic phenotype. The 
principle aims of this thesis were to investigate (i) how acquisition of endocrine 
resistance in breast cancer affected the cells’ angiogenic capacity and (ii) to 
identify the underlying pro-angiogenic mechanism(s). In order to achieve these 
aims, the following objectives were set: 
- To characterise the expression of pro-angiogenic factors in a panel of 
breast cancer cell lines.  
- To characterise the pro-angiogenic capacity of factors proven to be 
overexpressed in anti-hormone resistant breast cancers on the growth 
and migration of endothelial cell models (HUVEC, HECV). 
- To establish whether ex-vivo models of anti-hormone resistant breast 
cancer demonstrate differences in angiogenic responses.  
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Chapter 2: Materials and Methods 
2.1 Materials and Suppliers  
Below is a table of the materials and supplies used for the investigations 
detailed in this thesis, arranged alphabetically with the appropriate supplier. 
These suppliers are detailed at the end of the table. 
Material Supplier 
Activated charcoal S 
Agarose BL 
Ammonium persulfate (APS) S 
Anti-mouse horseradish-peroxidase-linked IgG (source: sheep) A 
Anti-rabbit horseradish-peroxidase-linked IgG (source: donkey) A 
Aprotinin S 
Arcrylamide/bis-acrylamide (30% solution (v/v), 29:1 ratio) S 
Bio-Rad DC Protein Assay (Reagents A, B and S) BR 
Bovine Serum Albumen S 
Bromophenol blue BDH 
Cell culture medium: RPMI 1640 and Phenol-red-free RPMI 1640 I 
Cell Proliferation Reagent WST-1 R 
Cell scrapers GB 
Chemiluminescent Supersignal® West HRP Substrate (Pico, Dura, 
Femto) 
P 
Coulter counting cups and lids SAG 
CryotubeTM vials (1.8ml, starfoot, round) N 
Dimethyl sulphoxide S 
Disposable cuvettes F 
Di-thiothreitol (DTT) S 
dNTPs (dAPT, dCTP, dTTP, dGTP; 100mM) A 
Endothelial Cell Growth Medium (Basal medium + Growth 
supplements) 
ECACC 
Ethidium Bromide (EtBr) S 
Ethylene diamine tetraacetic acid S 
Ethylene glycol-bis (2-amino-ethlether)-N,N,N’,N’-tetraacetic acid S 
Filter paper (Grade 3) W 
Filter paper (No.4) W 
Foetal Calf Serum (FCS) I 
General laboratory glass and plasticware F 
Glacial acetic acid F 
Glycerol F 
Glycine S 
Hydrochloric acid (HCL; 5M) F 
HyperladderTM IV BL 
Interleukin-8 (IL-8) S 
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Isoton® azide-free balanced electrolyte solution B 
Kodak MXB Autoradiography film (blue sensitive; 18cm x 24 cm) GR 
Leupeptin S 
L-glutamine I 
Lower buffer for SDS-PAGE gels (Tris 1.5M, pH 8.8) BR 
Molony-murine leukemia virus (MMLV) reverse transcriptase I 
N,N,N’,N’-tetramethylene-diamine (TEMED) S 
Nitrocellulose transfer membrane (Protran® BA85; 0.45μm pore size) S&S 
pH calibration buffers tablets (pH 4, 7 and 10) F 
Phenylarsine oxide S 
Phenylmethylsulfonyl fluoride (PMSF) S 
Pipette tips GB 
Polyoxoethylene-sorbitan monolaurate (Tween 20) S 
Ponceau S Solution (0.1% (w/v) in 5% acetic acid) S 
Precision Plus ProteinTM All Blue Standards (10-250kDa) BR 
Random hexamers (RH) A 
RNase-free H20 S 
Sodium azide S 
Sodium dodecyl sulphate (SDS) S 
Sodium fluoride (NaF) S 
Sodium hydroxide (NaOH; 5M) F 
Sodium molybadate (Na2MoO4) S 
Sodium orthovanadate (NaVO4) S 
Solvents (acetone, chloroform, ethanol, formaldehyde, isopropanol and 
methanol) 
F 
Sterile bijou tubes BB 
Sterile cell culture plasticware (i.e. flasks, dishes and plates) N 
Sterile Falcon tubes (15ml and 50ml) SAG 
Sterile phosphate buffered saline (PBS) I 
Sterile syringe filters (0.2μm) C 
Sterile universal containers (30ml) GB 
Taq DNA Polymerase (BioTaqTM; 5U/μl) BL 
TRI Reagent S 
Tris HCL S 
Triton X-100 S 
Trizma (Tris) base S 
Trypsin/EDTA 10x solution I 
Upper buffer for SDS-PAGE gels (Tris 0.5M, pH 6.8) BR 
Vascular Endothelial Growth Factor (VEGF) S 
Table 2.1 Materials and their suppliers. [A] Amersham, Little Chalfont, UK; [B] Beckman 
Coulter UK Ltd, High Wycombe, UK; [BDH] BDH Chemicals Ltd, Poole, UK; [BB] Bibby Sterlin 
Ltd, Stone, UK; [BL] Bioline Ltd, London, UK; [BR] Bio-Rad Laboratories Ltd, HERTS, UK; [C] 
Corning Inc., Corning, NY, USA; [ECACC] European Collection of Cell Cultures, Salisbury, UK; 
[F] Fisher Scientific UK Ltd, Loughborough, UK; [GR] Genetic Research Instrumentation, 
Rayne, UK; [GB] Greiner Bio-One Ltd, Gloucestershire, UK; [I] Invitrogen, Paisley, UK; [N] 
Nunc Int, Roskilde, Denmark; [P] Pierce and Warriner Ltd, Cheshire, UK; [R] Roche 
Diagnostics Ltd, Burgess Hill, UK; [S] Sigma-Aldrich, Poole, Dorset, UK; [SAG] Sarstedt AG 
and Co., Nümbrecht, Germany; [W] Whatman, Maidstone, UK; [S&S] Schleicher and Schuell, 
Dassell, Germany 
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2.2 Cell Culture 
2.2.1 Breast Cancer Cell Lines 
To model hormone sensitive breast cancer, MCF7wt (Michigan Cancer 
Foundation – 7) wild type (MCF7wt) cells were used as these cells represent an 
ER+, PR+ invasive ductal carcinoma. These cells have been are used 
extensively to study ER+, hormone-endocrine-responsive breast cancer. The 
MCF7wt cells used were a gift from AstraZeneca Pharmaceuticals but originally 
obtained from the American Type Culture Collection (ATCC Number HTB-22TM). 
MCF7wt cells were routinely cultured in RPMI + 5% foetal calf serum (FCS). For 
experiments where MCF7wt cells were used, they were maintained in 
experimental medium, wRPMI + 5% stripped foetal calf serum (SFCS) + 2% L-
Glutamine which is commonly referred to as w&5. wRPMI differs from RPMI in 
that it does not contain phenol red, as phenol red has an oestrogenic effect. In 
addition, stripped serum replaces whole serum and is produced by charcoal 
stripping whole serum. Charcoal stripping removes any lipophilic material in 
media such as lipid based growth factors, cytokines and importantly, steroid 
hormones. 
The T47D (ER positive, HER2 negative) breast cancer cell line, was used to 
represent a second model of ER+ breast cancer. These cells were purchased 
from the American Type Culture Collection (Manassas, VA). T47D cells were 
routinely cultured in RPMI + 5 % FCS and for experiments were cultured in 
experimental media. 
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2.2.1.1 Establishment of MCF7wt models of acquired tamoxifen and 
fulvestrant resistance  
As a model of acquired Tamoxifen resistance, ‘TamR’ cells were created by 
culturing MCF7wt cells in the presence of 4-hydroxytamoxifen (4-OH-T, 100nM) 
for a six month period. After an initial period of growth inhibition, cells begin to 
regrow (at around three to four months), suggesting they have acquired 
resistance to tamoxifen. These cells were maintained for a further three months 
to develop a stable phenotype after which the cells could then be used for 
routine cell culture. To maintain the selective pressure ensuring continued 
tamoxifen-resistance, cells were maintained in the presence of 4-
hydroxytamoxifen in w&5 (w&5+ 4-OH-T) (Knowlden et al., 2003).  
A model of acquired Faslodex resistance was developed by a similar method as 
above. MCF7wt cells were cultured over a period of twelve months in the 
presence of 100nM Faslodex to produce MCF7wt cells with acquired faslodex 
resistance (FasRs). These cells were routinely cultured in wRPMI + 5%SFCS + 
2% L-Glutamine and in the presence of 100nM Faslodex to maintain selective 
pressure, as with the TamR cell model.  
2.2.1.2 Oestrogen Deprived Cells 
To model a further acquired resistant state (aromatase inhibitor resistance), 
MCF7wt cells were grown in oestrogen deprived media (wRPMI + 5%XSFCS + 
2% L-Glutamine) for a period of three to six months to produce MCF7-X cells. 
The XSFCS used was charcoal stripped foetal calf serum that had been 
additionally heated to 65°C for 30 minutes to remove growth factors present in 
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the serum. They were routinely cultured in wRPMI + 5% XSFCS + 2% 
Glutamine. Breast cancer cell lines used are summarised in Table 2.2. 
 
 
 
 
 
 
 
 
 
 
Table 2.2 Characterisation of breast cancer cell lines used. ER, Oestrogen 
Receptor status; HER2, overexpression of HER2; PR, progesterone receptor status; 
TP53, protein levels and mutational status of TP53. Adapted from (Neve et al., 2006) 
2.2.1.3 Endothelial Cell Lines 
To investigate the behaviour of endothelial cells in response to various 
treatments we used the Human Umbilical Vein Endothelial Cell line (HUVEC) as 
well as a second endothelial cell line, Human Vascular Endothelial Cells 
(HECV). HUVEC cells were obtained from ECACC and maintained in 
specialised endothelial cell growth medium supplemented with a growth factor 
cocktail supplied with the medium both of which were also supplied by ECACC. 
Although the constituents of the growth factor cocktail are not defined by the 
company it does not contain PDGF or VEGF. HUVECs were only kept for a 
maximum of 9 passages as they are a primary cell line and prolonged culture 
results in senescence (Rhim et al., 1998).  
Cell line Gene 
Cluster 
ER PR HER2 TP53 
MCF7wt Luminal + + - +/-WT 
TamR Luminal + + -  
FasR Luminal - + -  
T47D Luminal + + - ++M 
MCF7wt-X Luminal + + -  
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HECV cells, a gift from Professor Wen Jiang, Cardiff University School of 
Medicine, and originally from Dr G. Di Domenico, Biology and Cellular and 
Molecular Pathology Dept, Naples, Italy are a more robust cell line that allows 
continuous culture allowing for longer experiments than HUVECs. HECV cells 
were routinely maintained in DMEM + 10% FCS whilst HUVECS were cultured 
in an endothelial cell growth media supplied by ECACC. Both cell lines were 
grown in w&5 when required for experiments. 
2.2.2 Cell Culture Techniques 
All cell-culture was carried out under sterile conditions in a MDH Class Laminar 
Flow Hood. All equipment and consumables were purchased sterile for single 
use or were sterilised at 119°C using an autoclave. Before use, the interior 
surfaces of the cabinets and the equipment within were sprayed with 70% (v/v) 
ethanol in water to ensure a sterile working environment. 70% ethanol can 
precipitate intracellular proteins in bacteria better than a higher concentration 
and so is the standard preparation for sterilisation use.  
Cells were typically maintained as monolayers in 75cm2 flasks (T-75) and grown 
in a Sanyo MCO-17AIC incubator (Sanyo E&E Europe BV, Loughborough, UK) 
at 37°C with a humidity atmosphere containing 5% CO2. The culture media was 
changed every 3 to 4 days and cells visually assessed for confluency during 
culture using a Nikon Eclipse TE200 phase-contrast microscope (Nikon-UK Ltd, 
Kingston-upon-Thames, UK) and passaged during log-phase growth 
(approximately 70-90% confluency.) 
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2.2.2.1 Passaging of Cells 
To passage cells, media was first removed and cell monolayers dissociated by 
the addition of 5ml of a trypsin/EDTA solution (0.05%/0.02% in PBS 
respectively). Trypsin is a proteolytic enzyme that causes detachment of cells 
from the growth surface by cleaving cell-cell and cell-matrix adhesions whilst 
EDTA acts to chelate Ca2+ and Mg2+ ions present in FCS that otherwise act as 
trypsin inhibitors. After addition of the trypsin/EDTA solution, the flasks were 
returned to the incubator for 3 to 5 minutes until the cells had detached. 
Trypsin/EDTA was neutralised with an equal volume of serum-containing media 
and the cells were pelleted by centrifugation for 5 minutes at 1000rpm. The cell 
pellet was gently re-suspended in 5ml of the appropriate medium and gently 
mixed to ensure no cell clumps were evident. A proportion of this suspension, 
typically 500µl (1/10 of cell suspension volume), was diluted in the appropriate 
medium and used to seed and additional T-75 flask which was then cultured as 
normal. Prior to setting up cells for an experiment, the re-suspended cells were 
counted using a CoulterTM Multisizer II Cell Counter (Beckman Coulter UK Ltd, 
High Wycombe UK) to enable seeding at an appropriate cell density. 
2.2.2.2 Cell Freezing 
To ensure an adequate supply of cellular material, stocks of established cell-
lines were generated by making up several suspensions of 1x106, low passage 
cells in 1ml of the appropriate media with a 10% concentration of FCS or SFCS 
and 7.5%DMSO. These cells were then placed in specialised cryotubes and 
frozen to -80°C for 24 hours. Following this cells were then placed in liquid 
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nitrogen for long-term storage. When required, cells were recovered from 
storage by removing the cryotubes from the liquid nitrogen and rapidly thawed 
to limit exposure of the cells to liquid DMSO. Once thawed, cells were removed 
to a sterile universal tube and diluted with ~9ml of the appropriate medium 
before being spun for 5min at 1000rpm to remove trace DMSO. Cells were 
transferred to the appropriate size flask, usually a T-25, and placed in an 
incubator at 37 C with 5% CO2 overnight. Medium was changed after 24 hours 
and cells then cultured as normal.  
2.2.3 Conditioned Media 
Conditioned media was obtained from MCF7wt, TamR, FasR and MCF7X cells 
as follows. Cell lines were cultured in their own specific growth medium until 
they reached ~70% confluency after which medium was replaced with 
experimental medium, w&5. These cells were returned to incubate at 37.5°C for 
4 days before 5ml of solution was collected, clarified by centrifugation for 5min 
at 1000rpm and filtered using a 0.2μm syringe filter. Media were stored at -20°C 
until required for further experiments.  
2.3 Micro-array Analysis 
An initial screen of pro- and anti-angiogenic factors expressed by breast cancer 
cell lines was examined at a gene level using microarray analysis. A list of 
factors implicated in angiogenesis was compiled from analysis of the literature 
and factors commonly included in commercially available angiogenesis pathway 
analysis kits. These genes were screened against our existing in-house 
microarray database based on a U133A gene array using GeneSifter software. 
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The TamR, FasR, T47D and MCF7-X arrays were interrogated for the mRNA 
expression of the genes from our list of angiogenic factors. These were all 
compared to the expression of the same factors by our MCF7wt array. Using 
the GeneSifter heat-map tool, the most significantly upregulated and 
downregulated genes in our cell lines compared to MCF7wt controls were 
determined. 
2.4 RT-PCR 
Gene expression in our breast cancer cell lines and in HUVEC and HECV cells 
after treatment with conditioned media was assessed using semi-quantitative 
reverse-transcription polymerase chain reaction (RT-PCR) as detailed below.  
2.4.1 RNA Extraction & Isolation 
Cells were seeded into 6-well plates at a density of 1.5x104 cells/well and 
cultured until they had reached log phase growth, then treated as indicated. 
Media was removed and cells were washed twice in PBS after which 150µl of 
TRI reagent was added to each well and allowed to stand for 5 minutes. The 
resulting lysate was passed through a pipette tip several times to ensure 
homogeneity of the sample, and transferred to a 1.5ml Eppendorf tube where 
they were allowed to stand for 5 minutes to ensure complete dissociation of the 
nucleoprotein complexes. To each ml of TRI Reagent, 200μl of chloroform was 
added followed by vortexing. Samples were left to stand for 10 minutes in order 
to separate the aqueous and organic phases of the lysate. The resulting mixture 
was centrifuged at 12,000rpm for 15 minutes at 4°C. This further separates the 
two mixtures into 3 phases: a lower red organic phase containing protein, a 
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white interphase containing DNA and a colourless upper aqueous phase 
containing RNA.  
The aqueous phase was transferred to a clean RNase-free Eppendorf and 
500μl of isopropanol was added to each, vortexed and allowed to stand for ~10 
minutes at room temperature. Samples were centrifuged at 12,000rpm for 15 
minutes at 4°C to precipitate the RNA. The supernatant was removed from the 
tube and the remaining pellet was washed in 1ml of 75% ethanol. The sample 
was mixed by vortex and centrifuged at 7,500rpm for 5 minutes at 4°C 
supernatant removed and pellets were air dried for 5-10 minutes but not allowed 
to dry completely as this would greatly reduce its solubility. The pellet was then 
dissolved in 20-50μl of RNase free distilled water and quantitated on a 
spectrometer by taking readings at 260nm (reads amount of nucleic acids) and 
280nm, from which the purity of the RNA sample and its concentration is 
calculated.  
2.4.2 Reverse Transcription (RT) 
All RT and further PCR work was carried out in a sterile enclosure. RNA was 
reverse transcribed using the Molony-murine leukaemia virus (MMLV) reverse 
transcriptase enzyme to generate cDNA that was complementary to mRNA 
samples used. The RT mixture contained total RNA, dNTP mix, to provide free 
nucleotides, dithiothreitol (DTT) to ensure RNasinTM activity in the next step, 
and random hexamers (RH) which act as random mRNA primers as well as RT 
buffer and RNase free water (sample volumes are detailed in Table 2.3). This 
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mixture is heated to 95°C in a PTC-100 thermocycler for 5 minutes to denature 
the RNA, and then quickly cooled on ice.  
To this denatured sample MMLV-RT and RNasinTM were added and returned to 
the thermocycler where it is heated to 22°C for 10 minutes, 42°C for 42 minutes 
and finally, 95°C for 5 minutes. 
Reagent 1 Sample 5 Samples 10 Samples 
5x RT Buffer 6µl 30µl 60µl 
0.1M DTT 3µl 15µl 30µl 
Random 
hexamers 
0.3µl 1.5µl 3µl 
25nm dNTPs 0.6µl 3µl 6µl 
RNase free 
water 
3.3µl 16.5µl 33µl 
RNAsin 1µl 5µl 10µl 
MMLV-RT 0.8µl 4µl 8µl 
Final Volume 15µl 75µl 150µl 
 
Table 2.3 Final reagent volumes in reverse transcription reaction mix. RT-Buffer, 
Reverse Transcription Buffer; DTT, dithiothreitol; dNTPs, deoxynucleotide 
triphosphates; MMLV-RT, Molony-murine leukaemia virus reverse transcriptase. 
2.4.3 Polymerase Chain Reaction (PCR) 
Each PCR reaction mixture used consisted of; dNTP mix, PCR buffer, MgCl2+, 
forward and reverse primers for sequences on the specific genes of interest 
(Table 2.5) as well as Taq polymerase enzyme in a 200μl Eppendorf. This 
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mixture was made up to 25μl with RNase free-dH20 and 1μg of total cDNA 
sample was added to each (sample volumes are detailed in Table 2.4). Each 
reaction was briefly mixed and centrifuges to ensure homogeneity before being 
placed in the thermocycler. Samples were run according to the following 
protocol; denaturation at 95°C for 5 minutes, then repeated cycles of 
denaturation, annealing at 55°C and extension at 72°C, commonly repeated for 
30 cycles before a final extension and cooling to 4°C. Depending on the primer 
pair used, variations were made on the number of cycles used and the 
annealing temperature. PCR data was normalised in the presence of β-actin, a 
housekeeping gene. To accomplish this, a PCR reaction was carried out for 
each cDNA sample using primers for β-actin. 
 
 
 
 
 
 
 
 
 
55 
 
Reagent 1 Sample 5 Samples 10 Samples 
25nM dNTPs 2µl 10µl 20µl 
PCR Buffer 2.5µl 12.5µl 25µl 
MgCl2+ 0.75µl 3.75µl 7.5µl 
Forward Primer 0.63µl 3.13µl 6.25µl 
Reverse Primer 0.63µl 3.13µl 6.25µl 
Taq  0.2µl 1µl 2µl 
RNase free 
water 
17.8µl 89µl 178µl 
Final Volume 24.51µl 122.55µl 245.1µl 
 
Table 2.4 Final reagent volumes in polymerase chain reaction mix. dNTPs, 
deoxynucleotide triphosphates.  
2.4.4 Agarose Gel Electrophoresis  
PCR products were separated and visualised using agarose gel electrophoresis 
as follows. 8µl of PCR sample were mixed with 10µl of loading buffer containing 
bromophenol blue and sucrose and loaded into a well of a 1% agarose gel (1% 
agarose in Tris-Acetate-EDTA [TAE] buffer containing 10mg/ml ethidium 
bromide). A DNA ladder measuring 100-1000Kb was used to mark product size. 
Gels were run in TAE buffer at 100 volts for 30 minutes prior to visualisation and 
photographing on a UV illuminator.  
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Gene Name 
 
Primer Sequence 
Predicted 
Product Size 
(bp) 
VEGF-A, Fwd 
VEGF-A, Rev 
5’CTGAAATGAAGGAAGAGGAG 
3’CACAGCAGTCAAATACATCC 
567bp 
VEGF-C, Fwd 
VEGF-C, Rev 
5’CGGGAGGTGTGTATAGATGTG 
3’ATTGGCTGGGGAAGAGTTTG 
583 
Il-8, Fwd 
Il-8, Rev 
5’ATGACTTCCAAGCTGGCCGT 
3’CCTCTTAAAAACTTCTCCACACC 
285 
VEGFR2, Fwd 
VEGFR2, Rev 
5’CAATGGAGGGGAACTGAAGAC 
3’TCTGGCTACTGGTGATGCTGT 
536 
VEGFR3, Fwd 
VEGFR3, Rev 
5’GAGCAGCCATTCATCAACAAG 
3’GGTAGTCCCAGTCAAAGGTG 
400 
Human IL-8 Receptor 
Alpha Fwd 
Human IL-8 Receptor 
Alpha Rev 
5’GCTAGGGCTAAGGTGTTTTC 
3’GTCCTCTTCAGTTTCAGCAA 
364 
Human IL-8 Receptor 
Beta Fwd 
Human IL-8 Receptor 
Beta Rev 
5’ATCTATGCCCTGGTATTCCT 
3’GGTCCTTCGGAAAAGTAAGA 
451 
HIF-1 Alpha Fwd 
HIF-1 Alpha Rev 
5’TCCATGTGACCATGAGGAAA 
3’CCAAGCAGGTCATAGGTGGT 
486 
β-Actin Fwd 
β-Actin Rev 
5’CTTTCTGGGTATGGAATCCT 
3’’GGAGCAATGATCTTGATCTT 
204 
Table 2.5 PCR Primers used and product size predicted for RT-PCR of 
proangiogenic factors in breast cancer cells. 
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2.5 SDS-PAGE/Western Blotting 
Changes in the basal expression or activation of proteins in response to 
treatments were assessed using SDS-PAGE and Western blotting with 
immunoprobing using phospho and total antibodies.  
2.5.1 Cell Lysis 
Cells were seeded into 6-well plates, 60mm or 100mm Petri-dishes at the 
required density and cultured until they reached log-phase growth, at which 
point they were treated indicated. Media was then aspirated from the dishes 
and cells were washed twice with ice-cold PBS solution before addition of 
Triton-X100 lysis buffer solution containing a cocktail of protease and 
phosphatase inhibitors as detailed below (Table 2.6).  
Inhibitor Final Concentration 
Sodium Orthovanadate 2mM 
Phenylmethylsulfonyl Fluoride 1mM 
Sodium Fluoride 25mM 
Sodium Molybadate 10mM 
Phenylarsine 20µM 
Leupeptin 10µg/ml 
Aprotinin 8µg/ml 
     
Table 2.6 Constituents of protease inhibitor cocktail.  
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Cellular material was collected using a cell-scraper and transferred to a 1.5ml 
Eppendorf, in which the lysates were homogenised briefly using a pipette before 
being clarified by centrifugation for 15 minutes at 13,000rpm, 4°C. The 
supernatant was then removed and stored at 20°C.  
2.5.2 Protein Concentration Assay 
To ensure equal protein loading for SDS-PAGE, the concentration of total 
soluble protein was determined using the Bio-Rad Dc Protein Assay kit (a 
modified version of the Lowry protein assay). A standard curve (such as in 
Figure 2.1) was constructed using increasing concentrations of BSA solution 
from 0 to 1.45mg/ml in TX100 lysis buffer to give 50µl solutions of each 
concentration. To this solution, 0.25ml of Reagent A (containing 5μl of Reagent 
S) and 2ml of Reagent B were added. The solutions were left for 10 minutes for 
full colour development and read on a Cecil CE2041 spectrophotometer (Cecil 
Instruments, Cambridge, UK) at 750nm, These readings were then compared 
with those of the BSA based standard curve to give the concentration of total 
soluble protein in the lysates.  
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Figure 2.1 Standard curve constructed from known BSA concentrations from 
which unknown concentrations of protein can be interpolated.  
 
2.5.3 SDS-PAGE Analysis 
SDS-PAGE (Sodium-Dodecyl-Sulphate-Polyacrylamide Gel Electrophoresis) 
was performed using a Bio-Rad Mini-Protean® III apparatus powered by a 
Powerpac BasicTM power pack (both from Bio-Rad Laboratories Ltd. Herts, UK). 
The gel system used was discontinuous, consisting of a 5% (w/v) 
acrylamide/bis-acrylamide stacking gel at pH6.8 and a typically 8-10% (w/v) 
acrylamide/bis-acrylamide resolving gel at pH8.8. 
A pair of glass plates, consisting of a cover and a backing plate, were cleaned 
with ethanol before being assembled in the gel casting apparatus, ensuring the 
plates were well clamped together to avoid leakage. The constituents of the 
resolving gel (Table 2.7) in the absence of TEMED were mixed in a universal 
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container before the addition of the catalyst as it would be adverse to cause 
polymerise and cross-linkage of the acrylamide and bis-acrylamide prematurely. 
After the addition of TEMED, the resolving gel was quickly and carefully mixed 
and dispensed between the two glass plates until the level reached 
approximately 1.5cm below the top of the plates (to allow room for the stacking 
gel). This space was topped-up with distilled water to prevent drying out of the 
gel and to create a level surface. Gels were left to set at room temperature for 
5-10 minutes.  
Once set the plates were rinsed in distilled water and any excess water was 
removed using sections of filter paper. Stacking gel was prepared, as described 
in Table 2.8, and on addition of the catalyst TEMED was carefully overlaid upon 
the resolving gel. Typically a 10-well comb mould was inserted into the stacking 
gel which was also allowed to set for 5-10 minutes at room temperature. Once 
set, moulding combs were removed and the gel was clamped into the 
electrophoresis apparatus and both inner and outer reservoirs of the tank were 
flooded with SDS-Page running buffer. 
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10ml 8% Gel (w/v) 
(70-200kDa) 
 
10ml 10% Gel 
(w/v) 
(20-100kDa) 
 
Final 
Concentration in 
Gel 
30% Acrylamide/bis-
acrylamide solution* 
2.7ml 3.3ml Varies with % Gel 
dH20 4.6ml 4.0ml - 
TRIS (1.5M, pH8.8) 2.5ml 2.5ml 375mM 
SDS (10% solution 
in H20) 
100µl 100µl 0.1%(w/v) 
APS (10% solution 
in H20) 
100µl 100µl 0.1%(w/v) 
TEMED 50µl 50µl 0.05%(v/v) 
Table 2.7 Constituents of the Resolving gel used for SDS-PAGE.            * Ratio of 
Acrylamide to bis-Acrylamide, 29:1 
  
10ml 5% Gel (w/v) 
 
Final Concentration in 
Gel 
30% Acrylamide/bis-
acrylamide solution* 
1.65ml 5%(v/v) 
dH20 5.7ml - 
TRIS (1.5M, pH8.8) 2.5ml 125mM 
SDS (10% solution in H20) 100µl 0.1%(w/v) 
APS (10% solution in H20) 50µl 0.05%(w/v) 
TEMED 25µl 0.2%(v/v) 
Table 2.8 Constituents of the Stacking gel used for SDS-PAGE.                                    
* Ratio of Acrylamide to bis-Acrylamide, 29:1 
Cell lysates containing a known amount of total soluble protein (15-150μg) were 
diluted as appropriate using 3 x Laemmli samples loading buffer and heated to 
100°C for 5-10 minutes to denature and reduce the proteins in the sample. The 
cell lysates, along with a protein molecular weight marker were carefully loaded 
into the wells of the stacking gel. Electrophoresis was then performed (Figure 
2.2) at 80mA (constant current) until the sample buffer dye had run the length of 
the gel.  
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Figure 2.2 SDS-PAGE Apparatus. Proteins migrate downwards through the gel with 
smaller proteins moving faster and therefore, further and larger proteins moving more 
slowly, therefore remaining near the top of the gel.  
2.5.4 Western Blotting 
Proteins were transferred from SDS-PAGE gels to a nitrocellulose membrane 
using Bio-Rad Mini-Protean® III apparatus. 
For each gel to be transferred, two pieces of grade 3 filter paper and one piece 
of Protran B85 nitrocellulose membrane (0.45μM pore size) were cut to the 
same size as the gel and pre-soaked along with two Teflon sponge pads, for at 
least 15 minutes in Western blot transfer buffer. Following electrophoresis the 
gel plates were separated, the stacking gel was carefully removed and 
discarded, and the resolving gel carefully transferred to a tray containing 
distilled water to wash off any excess SDS.  
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The Western blot transfer stack (Figure 2.3) was assembled following the 
manufacturer’s instructions in the order, positive electrode, sponge, filter paper, 
nitrocellulose membrane, SDS-PAGE gel, filter paper, sponge, negative 
electrode. A 50ml Falcon tube was used after the application of each layer, 
excluding the gel layer, to remove trapped air by gently rolling it across the 
surface of each layer. The cassette was then placed into the gel transfer 
apparatus with the gel (black side of cassette) nearest the negative (black) 
electrode and the membrane (clear side of the cassette) positioned near the 
positive electrode (red). The transfer apparatus was placed into a tank in the 
presence of an ice-block to prevent over-heating of the gel during transfer. The 
tank was then filled with transfer buffer and run at 100V constant voltage for 1 
hour.  
 
Figure 2.3 Set-up of transfer apparatus. Illustrating the flow of current through the 
acrylamide gel which causes migration of proteins into the nitrocellulose membrane 
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2.5.5 Immunoprobing of Western Blots  
Nitrocellulose membranes were removed from the transfer cassette and 
washed twice with Tris buffered saline (TBS). To assess integrity of the 
membranes and efficiency at which the transfer has been carried out 
membranes were washed briefly in Ponceau S solution (0.1% (w/v) in 5% acetic 
acid) which is then easily removed following several washes with 0.05% (v/v) 
TBS-Tween.  
After blocking in 5% (w/v) Marvel milk solution for 2 hours, the membrane was 
washed in TBS-Tween (2x5 minutes) and incubated overnight in a primary 
antibody specific for the protein of interest (Table 2.7). Primary antibodies were 
diluted in TBS-Tween containing 5% (w/v) Western Blocking Reagent and 
0.05% (w/v) sodium azide. The primary antibody dilution and incubation 
conditions used for each protein varied, and so, had to be optimised for each 
specific antibody.  
Table 2.7: Concentration of primary antibodies used for Western blotting 
analysis of relative protein levels 
Following primary antibody incubation the membrane was washed with TBS-
Tween (3x10 minutes) and incubated with the appropriate secondary antibody 
Primary Antibody Concentration Used 
VEGFR2 1:1,000 
p-MAPK 1:1,000 
p-Akt 1:1,000 
p-Src 1:1,000 
GAPDH 1:50,000 
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diluted in TBS-Tween containing 5% Western blocking reagent. Secondary 
antibodies were typically used at a dilution of 1:10,000 and incubation was for 1 
hour at room temperature. Further washes in TBS-Tween (4x10 minutes) and 
TBS (2x10 minutes) followed, before antibodies bound to the protein of interest 
were visualised using enhanced chemiluminescence (ECL).  
Chemiluminescence was performed using a luminol/peroxide based ECL 
reagent (SuperSignalTM West Pico, SuperSignalTM West Dura or SuperSignalTM 
West Femto). The ECL reagent (500μl) was made following the manufacturer’s 
instructions and carefully pipetted over the blot within a light-proof cassette. 
Luminol in the ECL reagent is oxidised by HRP in the presence of peroxide to 
produce an excited state product, which then decays to a lower energy state by 
releasing photons of light. This light is captured on x-ray film, with exposures 
ranging from seconds to hours depending on signal strength. X-ray films were 
developed using an X-O-graph Compact X2 X-ray developer and the bands 
obtained were scanned and analysed using a Bio-Rad GS-690 Imaging 
Densitometer.  
2.6 ELISA for VEGF Concentration in Conditioned Media  
ELISA plates were coated with capture antibody (0.5µg/ml) overnight before 
being washed (x4) in 0.05% Tween-20 in PBS and treated with block buffer (1% 
BSA in PBS, sterile filtered) for an hour at room temperature. A standard curve 
was constructed by using a range of VEGF concentrations (0 – 1ng/ml) and 
samples of unknown concentration were added to each well of the ELISA plate 
in triplicate and incubated at room temperature for 2 hours.  
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After incubation with plates were washed and blotted dry before addition of 
0.25µg/ml detection antibody and incubation for 2 hours at room temperature. 
After washing and blotting of plates, avidin-HRP was made up to 0.5µl/ml in 
diluent and 100µl was added to each well. Plates were left to incubate for 30min 
at room temperature. After a final washing and blotting step, 100µl of ABTS 
solution (which acts as a substrate for peroxidase linked antibodies) was added 
to each well and the plates monitored for the development of a colour change 
which was read on a spectrophotometer (absorbance read at 405nm, reference 
at 650nm). 
2.7 MTS Cell Proliferation Assay 
The cell proliferation reagent MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) involves 
the metabolism of the tetrazolium salt to fomazan, a dark red product by cellular 
enzymes (Cory et al., 1991). An increased number of viable cells results in an 
increase in mitochondrial dehydrogenase enzymes in the sample and therefore 
an increased amount of fomazan dye formed, which is directly correlated with 
the number of viable cells in the sample.  
HUVEC cells were set-up on ‘Day 0’ in 96-well plates at a confluency of 
2000cells/well. Cells were allowed to settle overnight in their growth medium 
before being quiesced for 12 hours in serum deprived medium on ‘Day 1’. On 
‘Day 2’ cells were treated by aspirating quiescent media and replacing it with 
conditioned media and appropriate controls.  
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Cells were left in treatment media for a further 1, 3 and 5 days before media 
was aspirated and a solution of 10% MTS reagent in wRPMI was added. Cells 
were incubated at 37°C for 2 hours before being read in a microplate reader at 
450nm with a reference reading of 650nm.  
Optimisation of the MTS assay involved finding an appropriate incubation time 
within the 0.5 – 4 hour range, and it was found that incubation for 2 hours 
resulted in the ideal absorbance readings to show a proliferative effect without 
becoming saturated. 
2.8 Tubule Formation Assay 
To assess the ability of conditioned media from breast cancer cells to promote 
endothelial tubule formation (Kubota et al., 1988), HUVECs were cultured in 
conditioned media on a Matrigel base layer. Neat Matrigel was dispensed into 
the wells of the 96-well plate and placed in an incubator for an hour to set. 
HUVECs were harvested using Trypsin/EDTA and resuspended in growth 
serum deprived medium before being seeded at a cell density of 15,000 
cells/10μl of medium. These cells were made up to a final volume of 100μl in 
separate aliquots of conditioned media and appropriate controls before being 
dispended into the Matrigel coated 96-well plate. Cells were returned to the 
incubator at 37°C with 5% CO2 for 1 hour after which, they were removed and 
photographed using a light microscope at x10 magnification and digital camera 
light-microscope attachment. Matrigel was kept at 4°C to prior to usage in order 
to prevent premature gelling. 96-well plates and pipette tips were cooled to -
20°C to prevent increasing the temperature of Matrigel while dispensing. 
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2.9 Electronic Cell-Substrate Impedance Sensing (ECIS) 
The effect of breast cancer cell conditioned media on the permeability of an 
endothelial cell monolayer can be determined using electronic cell-substrate 
impedance sensing (ECIS) (Giaever et al., 1993). ECIS is a dedicated system 
to measure the resistance across a cell monolayer. At the heart of the system 
are plastic arrays on which cells can be cultured and treated (Figure 2.4). These 
arrays possess gold electrodes on their surfaces which create a measureable 
electrical current that can be continually measured. Through a computer 
program that monitors this current, they may be used to determine the fidelity of 
a cell monolayer and whether or not this can be disrupted or enhanced by 
external factors, in this case, those present within breast cancer cell-conditioned 
media. In the event that a particular treatment disrupts endothelial cell-cell 
interactions, a detectable drop in resistance can be observed.  
Figure 2.4 8W10E ECIS array; on which endothelial cells may be grown and 
subsequently treated to determine the effects of treatment on: cell attachment and 
migration, wound healing and metastatic potential 
For our work, we used the ECIS Zθ (Applied Biophysics, Wold Laboratories Ltd. 
UK) system for measuring cell-cell adhesion of endothelial cells, (HECV cells). 
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This system was based in Cardiff University’s School of Medicine within 
Professor Jiang’s group. ECIS arrays were precoated with cysteine before use 
for 30 minutes to bind the gold surface and produce a molecular monolayer 
which is known to increase reproducibility Array wells were then flooded with 
serum-containing medium for 15 minutes to allow serum proteins to be 
adsorbed by the array monolayer. Following pre-treatment, HECV cells were 
trypsinised and counted, before seeding out at a cell concentration of 300,000 
cells per array well. ECIS arrays were then immediately placed in the incubator 
and connected to the docking stations after which recording was begun. Using 
the computer associated with the ECIS equipment, impedance was assessed 
continually over 24 hours. When a plateau of impedance was observed, 
exhibiting an established monolayer of cells, arrays were removed and growth 
media were replaced with treatment media. After culturing for 48 hours, arrays 
were removed and data were analysed using the ECIS program software.  
2.10 Chick Chorioallantoic Membrane Assay 
Assessment of the effect of conditioned media treatment on in vivo 
angiogenesis was assessed using the chick chorioallantoic membrane (CAM) 
assay. Fertilised eggs were purchased chilled at 12°C to slow development of 
the embryo without reducing viability. These eggs may be stored at 12°C for up 
to one week before viability begins to deteriorate. On receipt of eggs they were 
transferred to a specialised egg incubator (Brinsea Mini ECO) that maintains 
temperature at 37.5°C and rotates eggs periodically to improve survivability by 
mimicking natural incubation procedures.  
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On day three post-fertilisation, eggs were prepared by spraying with 70% 
ethanol which reduced contamination risk. A small hole was bored in the wider 
end of the egg to depressurise the air sac. To ensure that removal of shell does 
not result in albumin or yolk spilling some albumin was removed prior to 
windowing. Eggs were laid on their side to allow removal of 2 to 3 ml of albumin 
using a syringe inserted into the pre-made hole. Care was taken to avoid 
disruption or removal of yolk as this can seriously reduce embryonic viability. 
The hole was then sealed using tape. Following this, eggs were pierced by 
inserting a sharp tweezers into the side of each egg ensuring not to apply 
surplus force which can result in breaking of shells. From this initial hole, an 
approximately 1cm2 window is made allowing observation of the developing 
embryo. This hole is then covered with tape and returned to the incubator 
overnight.  
The following day (4 days post initial incubation), embryos were examined for 
viability. Embryos were determined to be viable if vessels are intact, the embryo 
continues to move and there is no discolouration of the yolk. Viable embryos 
were deemed suitable for testing of angiogenic stimuli. Heat sterilised filter 
paper was soaked in w&5 media or conditioned media from MCF7wt and TamR 
cell lines for 1 hour prior to treatment of CAM tissue. Filter papers were placed 
on CAM tissue proximal to embryos with one treatment (MCF7wt or TamR 
conditioned media) and one control on each embryo. Exposed CAM tissue was 
covered with tape and eggs were returned to the incubator.  
Following treatment, eggs were removed from the incubator daily and 
photographed in situ to observe gross vascular changes and determine whether 
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these were directed towards the filter papers impregnated with conditioned 
media from our cell lines.  
2.11 CD31 Immunohistochemistry on Breast Cancer Cell Xenografts  
Paraffin embedded sections (3nM) of MCF7wt and TamR mouse xenografts 
(courtesy of Mr Chris Smith and Dr Julia Gee) were dewaxed by soaking twice 
in xylene for 7 minutes. Samples were presented as two sections of tissue per 
slide (one to act as a control). These samples were then rehydrated by soaking 
in decreasing concentrations of ethanol for 3 minutes twice (100%, 90% and 
70% respectively) before being place in a trough of distilled water for 5 minutes. 
Samples were transferred to a coplin jar containing PBS for 5 minutes. Slides 
were then transferred into a humidity chamber with a single drop of 3% 
hydrogen peroxidase solution, which functions to eliminate endogenous 
peroxidases that can interfere with the specificity of an assay. Using pre-made 
citrate buffer (10mM Sodium citrate, pH 6.0) antigen retrieval was carried out 
using a pressure cooker for 2 minutes. Samples were then gradually cooled 
with slow running tap water before control and test samples were separated on 
each slide using a Dako, water repellent pen. Slides were soaked briefly in 
0.5% Tween-20 in PBS. Primary antibody was then added to test samples on 
each slide (1/15 dilution of 1µg/ml rat anti-mouse CD31 primary antibody). 
Slides were transferred to a humidity chamber and placed in an incubator set to 
23°C overnight. The following day, slides were washed twice with PBS for 5 
minutes, followed by one wash with 0.5% Tween-20 in PBS. At this point, 
secondary antibody was applied to both test and control samples on each slide 
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(1/50 dilution of goat anti-rat HRP linked antibody). Slides were then incubated 
in humidity chambers placed in an incubator set to 23°C for 2 hours. Following 
incubation with secondary antibody, slides were washed by dipping in Tween-
PBS solution.  
To develop HRP linked antibody, DAB (3’3’-diaminobenzidine) substrate 
solution, which stains brown in the presence of HRP was prepared as per then 
manufacturer’s instructions and 50µl of DAB solution was applied to each 
sample and incubated at room temperature for 10 minutes. Slides were washed 
in distilled water for 5 minutes twice before the addition of counterstain (10% 
haematoxylin in distilled water) for 10 minutes. Excess stain was removed by 
rinsing slides, placed in a coplin jar under a cold water source for 5 minutes to 
blue. Finally slides were mounted in DPX (di-n-butylphthalate in xylene) 
solution.  
Analysis of CD31 staining was carried out by randomisation of MCF7wt and 
TamR slides before imaging of 5 random sections from the outer and inner 
parts of each sample using a light-microscope. Images were then overlaid with 
a counting grid that divided samples into 1mm2 squares which allowed analysis 
of large and small cell groups based on the following criteria; large vessels 
occupied an area greater than one grid, medium vessels transected between 
two and three sides of one counting grid, and small vessels only transected one 
side of a counting grid. Total counts of large, medium and small vessels were 
made for inner and outer sections of each sample before they were grouped as 
MCF7wt and TamR.  
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2.12 Rat Aortic Ring Assay 
Tissue was obtained from 150g Sprague-Dawley rats that were sacrificed by 
bleeding from the right femoral artery under anaesthetic (phenobarbital). 
Excision of the descending thoracic artery was performed before tissue was 
washed with sterile PBS to remove trace blood. Tissue sections were debrided 
of fibrous and adipose tissue using a scalpel before being cut into 1mm 
transverse sections. These sections were then embedded in a Matrigel plug in 
separate wells of a 12-well plate. Sections were treated with conditioned media 
from MCF7wt and TamR cells as well as appropriate controls (w&5 as a 
negative control and VEGF 10ng/ml as a positive control). These were then 
returned to incubators and allowed to grow over 10 days at 37°C. Media were 
changed on day 5 of culture. Formation of tubule structures was observed over 
the course of the experiment by taking photos daily and counting the structures 
observed in 5 random fields for each section. 
2.13 Data Analysis and Statistics 
GraphPad Prism version 5.01 was used to analyse data. Student’s independent 
t-test was used for analysis of all results comparing pairs of data while one-way 
analysis of variance tests with Tukey’s multiple comparison tests used for 
comparing more than two groups of data. All data were considered significant 
when p≤0.05. Results are, where appropriate, expressed as mean ±SEM.  
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Chapter 3: Characterisation of Pro-angiogenic Signalling in 
Endocrine-Sensitive and Endocrine-Resistant Breast Cancer 
Cells 
3.1 Introduction and Aims 
In the treatment of ER+ breast cancer the use of anti-oestrogen therapy using 
tamoxifen has been shown to be effective in suppressing tumour growth and 
preventing recurrent disease, providing benefit up to five years post treatment 
(Powles et al., 2007). Despite this, around two-thirds of patients receiving 
tamoxifen will relapse with resistant disease (Dorssers et al., 2001). Resistant 
disease frequently occurs as metastasis clinically and is associated with a poor 
prognosis (Ring et al., 2004).  
Acquired resistance to tamoxifen has been associated with elevated expression 
and activity of growth factor receptors such as EGFR and HER2, as well as 
intracellular kinases that drive survival, proliferation (Gee et al., 2005) and other 
aggressive cell behaviours such as motility and invasion (Hiscox et al., 2004). 
Whether acquired endocrine resistance affects the cells pro-angiogenic capacity 
remains unknown. Therefore, we sought to investigate whether there are 
changes in the regulation of angiogenesis which may prove to be functionally 
important in explaining phenotypical changes that are present on acquisition of 
endocrine resistance.  
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3.2 Results 
3.2.1 Microarray Analysis of Pro-Angiogenic Factor Expression 
To explore whether the gain in aggressive cellular characteristics extended to 
an angiogenic phenotype, our in-house microarray database of ER+, endocrine-
sensitive (MCF7wt, T47D cells), ER+, endocrine-resistant (TamR, MCF7X cells) 
and ER-, faslodex-resistant MCF7wt cells was screened for the presence of 
genes with a pro-angiogenic ontology (Burmi et al., 2006). 
In studying whether the factors that regulate angiogenesis were altered on 
acquisition of anti-oestrogen resistance, a list of genes encompassing pro- and 
anti-angiogenic factors was compiled from a selection of papers reporting 
factors found to be associated with pro-and anti-angiogenic ontologies (Hoeben 
et al., 2004; Robert, 2007; Roy et al., 2006) as well as pro-angiogenic pathways 
from online sources (Cell Signalling, 2012). This list was screened using our in-
house microarray database encompassing MCF7wt, TamR, FasR, X-cells and 
T47D cell arrays.  
We investigated the expression of 322 genes that included pro-angiogenic 
factors including; FGF, VEGF and PDGF as well as negative regulators such 
as; Angiopoietin 2 and TSP-1. We used GeneSifter software to identify the most 
statistically significant upregulated and downregulated genes from our dataset 
between pairs of in vitro cell lines.  
Array data comparing MCF7wt gene expression to that of TamR for the factors 
we selected (Figure 3.1) illustrated that the TamR cell line had higher 
expression levels of pro-angiogenic ligands such as VEGF and IL-8. In addition, 
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the levels of the anti-angiogenic glycoprotein Thrombospondin 1 were seen to 
be decreased in TamR cells in comparison to MCF7s.  
Examination of array data for MCF7wt cells when compared to FasRs (Figure 
3.2) demonstrated that there is an increased expression of interleukin-8 and 
despite also having a reduced expression of THBS1, there is also a reduction of 
positive regulators of angiogenesis such as VEGF-C.  
Array data that compared MCF7wt expression profiles for angiogenic factors to 
those that came from array data examining oestrogen-deprived MCF7wt cells 
(MCF7X cells, a model of oestrogen deprivation) demonstrated a significant 
increase in the expression of VEGF-A (Figure 3.3). Figure 3.4 shows the most 
significantly upregulated and downregulated genes from the regulators of 
angiogenesis we examined in T47D cells versus MCF7wt cells. Here, we saw 
an increased number of negative angiogenic regulators being upregulated 
compared to MCF7wt.  
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Figure 3.1 Expression profile of regulators of angiogenesis in TamR vs. MCF7wt 
cells using the Affymetrix HG-U133A cDNA array.  
MCF7wt and TamR cells were cultured under basal conditions to log-phase growth after which point they were 
harvested for total RNA using TriReagent (Sigma). RNA samples were DNAse1 treated to remove genomic DNA 
and purified using the Quiagen RNeasy mini kit. RNA samples were then quantified and tested for RNA integrity 
by spectrophotometry before being applied to Affymetrix HG-U133A Genechip analysis (Central Biotechnology 
Services, Cardiff University, Cardiff, UK). The Genechip arrays were scanned and analysed using the Microarray 
Suite 5.0 software (Affymetrix) and the quality of the data was verified through analysis of internal control gene 
expression. The gene expression profiles for the regulators of angiogenesis show above, presented as the most 
significantly upregulated and downregulated genes from the selection.  
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Figure 3.2 Expression profile of regulators of angiogenesis in FasR vs. MCF7wt 
cells using the Affymetrix HG-U133A cDNA array.  
MCF7wt and FasR cells were cultured under basal conditions to log-phase growth after which point they were 
harvested for total RNA using TriReagent (Sigma). RNA samples were DNAse1 treated to remove genomic DNA 
and purified using the Quiagen RNeasy mini kit. RNA samples were then quantified and tested for RNA integrity 
by spectrophotometry before being applied to Affymetrix HG-U133A Genechip analysis (Central Biotechnology 
Services, Cardiff University, Cardiff, UK). The Genechip arrays were scanned and analysed using the Microarray 
Suite 5.0 software (Affymetrix) and the quality of the data was verified through analysis of internal control gene 
expression. The gene expression profiles for the regulators of angiogenesis show above, presented as the most 
significantly upregulated and downregulated genes from the selection.  
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Figure 3.3 Expression profile of regulators of angiogenesis in MCF7-X vs. 
MCF7wt cells using the Affymetrix HG-U133A cDNA array.  
MCF7wt and MCF7-X cells were cultured under basal conditions to log-phase growth after which point they were 
harvested for total RNA using TriReagent (Sigma). RNA samples were DNAse1 treated to remove genomic DNA 
and purified using the Quiagen RNeasy mini kit. RNA samples were then quantified and tested for RNA integrity 
by spectrophotometry before being applied to Affymetrix HG-U133A Genechip analysis (Central Biotechnology 
Services, Cardiff University, Cardiff, UK). The Genechip arrays were scanned and analysed using the Microarray 
Suite 5.0 software (Affymetrix) and the quality of the data was verified through analysis of internal control gene 
expression. The gene expression profiles for the regulators of angiogenesis show above, presented as the most 
significantly upregulated and downregulated genes from the selection.  
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Figure 3.4 Expression profile of regulators of angiogenesis in T47D vs. MCF7wt 
cells using the Affymetrix HG-U133A cDNA array.  
MCF7wt and T47D cells were cultured under basal conditions to log-phase growth after which point they were 
harvested for total RNA using TriReagent (Sigma). RNA samples were DNAse1 treated to remove genomic DNA 
and purified using the Quiagen RNeasy mini kit. RNA samples were then quantified and tested for RNA integrity 
by spectrophotometry before being applied to Affymetrix HG-U133A Genechip analysis (Central Biotechnology 
Services, Cardiff University, Cardiff, UK). The Genechip arrays were scanned and analysed using the Microarray 
Suite 5.0 software (Affymetrix) and the quality of the data was verified through analysis of internal control gene 
expression. The gene expression profiles for the regulators of angiogenesis show above, presented as the most 
significantly upregulated and downregulated genes from the selection.  
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3.2.2 Selection and Validation of Pro-Angiogenic Factor Expression 
in Breast Cancer Cell Lines 
 
The information obtained from the Affymetrix dataset revealed significant 
deregulation of pro- and anti-angiogenic molecules in cell models of acquired 
anti-oestrogen resistance. This list was interrogated to select a number of 
factors based on whether: (i) they were positive regulators of angiogenesis and 
were upregulated in endocrine-resistant cell lines vs. the endocrine-sensitive 
MCF7wt cells; (ii) a well-established role in angiogenesis; (iii) potential 
targetability and finally (iv) possessed a link with existing data concerning our 
acquired resistant cell lines.  
A major factor influencing the selection of these genes was that our cell models 
of resistance are known to possess elevated FAK and Src activity. These 
molecules are known to be deregulated after acquisition of tamoxifen resistance 
in MCF7wt cells (Hiscox et al., 2006b; Planas-Silva et al., 2006).  
The two factors chosen to be taken forward were VEGF and IL-8. IL-8 was the 
most highly upregulated factor in TamR vs. MCF7wt and the second highest in 
FasR vs. MCF7wt analysis. VEGF, which is well established as a pro-
angiogenic factor was also significantly upregulated in TamR vs. MCF7wt. Both 
of these molecules are well characterised in the literature and so, would not be 
difficult to obtain inhibitors, ligands or other tools for examination of their 
function and the role they may play in altered angiogenesis of endocrine-
resistant breast cancer cells (Dai et al., 2007; Li et al., 2003). Both FAK and Src 
have been shown to influence the expression of IL-8 and VEGF respectively 
(Eliceiri et al., 1999; Eliceiri et al., 2002; Summy et al., 2005; Trevino et al., 
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2005) and therefore may represent a mechanism through which VEGF and IL-8 
are overexpressed in the resistant cell models. Moreover, access to 
pharmacological inhibitors selective for these molecules would potentially allow 
us to further investigate the role of FAK/Src in the angiogenic capacity of our 
resistant cells. 
3.2.3 Validation of VEGF and IL-8 Gene Expression in Endocrine-
Sensitive and Resistant Breast Cancer Cells 
Elevated expression of VEGF and IL-8 could contribute to a more angiogenic 
phenotype in endocrine-resistant cells and so, examination of mRNA 
expression of these ligands was carried out using semi-quantitative RT-PCR on 
RNA from our panel of breast cancer cells. These cells were grown under the 
same culture conditions as that in which the functional assays were performed. 
PCR products were resolved on 2% agarose gels with ethidium bromide and 
bands were analysed using densitometry.  
Analysis of IL-8 expression across our in vitro cell lines (Figure 3.5) revealed 
that it was upregulated in all four cell lines examined, however, this was only 
significant in TamR cells when compared to MCF7wt cells. Expression of 
VEGF-A was greatly increased in TamR cells vs. MCF7wt as is VEGF-C.  
83 
 
Figure 3.5 Basal IL-8 and VEGF levels in breast cancer cell lines as measured by 
semi-quantitative PCR 
MCF7wt, TamR, FasR, X-Cell and T47D cells at 70% confluency were cultured in wRPMI + 5% 
foetal calf serum + 2% glutamine for 96 hours. Total RNA was then extracted from these cells 
using TriReagent as per the manufacturer’s instructions. IL-8, VEGF-A and VEGF-C levels were 
determined by RT-PCR using specific primers and the PCR products were resolved on a 2% 
agarose gel using ethidium bromide electrophoresis. Bands were analysed by densitometry and 
data, corrected using Beta-actin, are presented as mean % control ± SEM, n=3; *, p<0.005 vs. 
MCF7wt; **, p<0.0001 vs. MCF7wt.  
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3.2.4 VEGF but not IL-8 Induces Endothelial Cell Proliferation  
Having confirmed that VEGF and IL-8 gene expression were both higher in 
TamR cells compared to their endocrine-sensitive MCF7wt counterparts, we 
sought to investigate whether this was responsible for the increases seen in 
endothelial cell proliferation. Thus, we investigated the response of endothelial 
cells to purified VEGF and IL-8 using MTS assays.  
Whilst treatment with VEGF resulted in a dose-dependent increase in 
endothelial cell growth (Figure 3.6), IL-8 did not have any significant effect on 
proliferation (Figure 3.7). Interestingly, at low concentration IL-8 appeared to be 
growth suppressive.  
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Figure 3.6 Dose response of VEGF stimulation on HUVEC cell proliferation 
HUVEC cells were seeded onto 96-well plates in basal media and grown to 70% confluency 
before being quiesced in serum free media for 24 hours. Following this, media were removed 
and endothelial cells were treated with increasing concentrations of VEGF. Cell proliferation 
was assessed using MTS reagent. Data are presented as % Control ± SEM (n=3) 
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Figure 3.7 Dose response of IL-8 stimulation on HUVEC cell proliferation 
HUVEC cells were seeded onto 96-well plates in basal media and grown to 70% confluency 
before being quiesced in serum free media for 24 hours. Following this, media were removed 
and endothelial cells were treated with increasing concentrations of IL-8 in w&5 or a w&5 
control. Cell proliferation was assessed using MTS reagent. Data are presented as % Control ± 
SEM (n=3) 
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3.3 Analysis of VEGF Protein Expression in Breast Cancer Cell 
Conditioned Medium 
Having identified that VEGF but not IL-8 stimulated HUVEC growth, we next 
sought to characterise breast cancer conditioned media for VEGF protein using 
ELISA. These data illustrated that VEGF was increased in media from 
endocrine-resistant breast cancer cell lines, TamR, FasR and T47D but only 
significantly in the TamR cell media (Figure 3.8).  
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Figure 3.8 Basal protein levels of VEGF in conditioned media taken from breast 
cancer cell lines as measured by ELISA.  
MCF7wt, TamR, FasR, X-Cell and T47D cells were grown in w&5 for a period of 4 days after 
which conditioned media was collected, clarified and stored at -20
o
C. ELISA was performed on 
conditioned media and protein concentrations were normalised to cell counting experiments 
performed after collection of media. Data are mean VEGF in pg/ml of media and are shown ± 
SEM. ***, p<0.0001 vs. Control (n=3).  
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3.3.1 Exploration of VEGF Production by TamR cells: HIF-1α 
Typically, regulation of angiogenesis is under the control of HIF 1-alpha (Pugh 
et al., 2003). Under hypoxic conditions the breakdown of HIF-1α is inhibited 
which frees the transcription factor to bind DNA and upregulate the expression 
of several genes implicated in angiogenesis. To assess whether altered HIF-1α 
expression was contributing to the elevated VEGF seen in conditioned media 
taken from TamR cells we first examined the mRNA expression of the gene in 
breast cancer cells. RT-PCR analysis (Figure 3.9) of HIF 1-alpha expression did 
not show any alteration in expression of the gene at an mRNA level between 
the cell lines we examined. 
Examination of HIF1-α protein expression (Figure 3.10) revealed no significant 
difference between MCF7wt and TamR cell expression of the transcription 
factor although the expression level in FasR, MCF7X and T47D cell did 
demonstrate a lower level of the protein when compared to MCF7wt. 
Interestingly, alterations in the expression of HIF 1-alpha did not seem to 
correlate with differences seen in expression of VEGF and IL-8 (Figure 3.5).  
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Figure 3.9 Basal HIF1-alpha levels in breast cancer cell lines as measured by 
semi-quantitative PCR 
MCF7wt, TamR, FasR, X-Cell and T47D cells at 70% confluency were cultured in 
wRPMI + 5% foetal calf serum + 2% glutamine for 96 hours. Total RNA was then 
extracted from these cells using TriReagent as per the manufacturer’s instructions. 
HIF1-alpha levels were determined by RT-PCR using primers specific for HIF1-alpha 
and the PCR products were resolved on a 2% agarose gel using ethidium bromide 
electrophoresis. Bands were analysed by densitometry and data, corrected using Beta-
actin, are presented as mean % control ± SEM, n=3.  
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Figure 3.10 Basal levels of HIF1-alpha in breast cancer cell lines as determined 
by Western blotting 
MCF7wt, TamR, FasR, MCF7X and T47D cells were cultured from 70% in wRPMI + 
5% stripped foetal calf serum + 2% glutamine for 96-hours before being lysed for 
proteins as described previously. Total soluble protein (20µg/lane) was subjected to 
SDS-PAGE and Western blot analysis before membranes were probed with antibodies 
specific for HIF 1-alpha (A). Densitometry was conducted on the bands obtained and 
the data, which were corrected for loading with GAPDH are presented as mean % 
control (MCF7wt) ± SEM, n=3.  
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3.3.2 Exploration of VEGF Production by TamR Cells: ER 
Several groups have published data linking regulation of VEGF to oestrogen 
receptor signalling (Buteau-Lozano et al., 2002; Ruohola et al., 1999), although 
not all reports demonstrate this (Bogin et al., 2002; Hyder et al., 1998). 
Nevertheless, considering endocrine resistance occurs as a consequence of 
altered ER signalling, we sought to examine whether this would affect the 
production of VEGF by our tamoxifen resistant cells. In addition, we sought to 
determine whether ER stimulation or inhibition in our endocrine-sensitive 
MCF7wt cells would have any effect on their VEGF production.  
Examination of VEGF concentration in conditioned media (Figure 3.11) from 
MCF7wt and TamR cells treated with tamoxifen, faslodex, oestradiol or control 
media illustrated that there was no significant difference between any treatment 
group and the control for that group.  
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Figure 3.11 VEGF Concentration in conditioned media taken from breast cancer 
cell lines that were treated for 4 days with endocrine agents 
MCF7wt and TamR cells were set up in experimental media and allowed to settle 
overnight before media were replaced with w&5 containing Tamoxifen (4x10-7M), 
Faslodex (1x10-7M) or E2 (1x10-9M). Media were collected 96 hours later and an ELISA 
was performed to determine VEGF concentration in each sample. Media were 
normalised to total cell counts, determined at 96 hours post treatment. All results were 
ns compared to MCF7wt control. 
 
 
 
3.3.3 Exploration of VEGF Production by TamR Cells: Src kinase 
TamR cells possess elevated signalling through several growth factor pathways 
which results in increased phosphorylation of downstream second messengers 
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such as MAPK and Akt (Figure 3.12). Previous work (S. Hiscox, unpublished 
data) has already suggested a role for Src kinase, a factor known to be 
upregulated in acquired anti-oestrogen resistance models, as a key regulator of 
pro-angiogenic signalling. In addition we were able to inhibit the main Src-family 
member using a small molecule inhibitor, Saracatinib (AZD0530). Examination 
of ELISA data from experiments carried out on conditioned media taken from 
TamR cells that had been pre-treated with the drug (Figure 3.13) illustrated that 
removal of Src kinase signalling leads to a significant reduction in the 
production of VEGF by the cell. Inhibition of other intracellular kinases (Figure 
3.13) known to be upregulated in TamR cells in comparison to MCF7wts 
illustrated that the removal of MAPK and PI3K/Akt signalling at doses known to 
reduce their activity, does not have a significant effect on the reduction of VEGF 
production by TamR cells. 
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Figure 3.12 Basal levels of intracellular signalling molecules in MCF7wt and 
TamR cells as determined by Western blotting 
A. MCF7wt and TamR cells were cultured from 70% in wRPMI + 5% stripped foetal calf 
serum + 2% glutamine for 96-hours before being lysed for proteins as described 
previously. Total soluble protein (20µg/lane) was subjected to SDS-PAGE and Western 
blot analysis before membranes were probed with antibodies specific for phospho-
MAPK, phospho-Akt and phospho-Src (A).  
B. Densitometry was conducted on the bands obtained and the data, which were 
corrected for loading with GAPDH are presented as mean % control (MCF7wt) ± SEM, 
n=3.  
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Figure 3.13 Basal protein levels of VEGF in conditioned media taken from breast 
cancer cell lines as measured by ELISA ± Src inhibition.  
TamR cells were grown in wRPMI + 5% stripped foetal calf serum + 2% glutamine ± 
1µM saracatinib OR 1µM UO126 OR 1µM LY-2940002 for a period of 4 days after 
which conditioned media was collected, clarified and stored at -20oC. ELISA was 
performed on conditioned media and protein concentrations were normalised to cell 
counting experiments performed on collection of media. Data are mean VEGF in pg/ml 
of media and are shown ± SEM. ***, p<0.00001 (n=3).  
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3.4 Discussion 
The aim of this chapter was to determine the extent of the deregulation of 
angiogenic factors in endocrine-resistant breast cancer cells and to conduct a 
preliminary exploration of a mechanism by which this occurs.  
3.4.1 Basal Angiogenic Characteristics of Breast Cancer Cells 
Resistance to treatment with anti-oestrogens is a major clinical problem and the 
aggressive phenotype associated with acquisition of resistance is of serious 
concern. The presence of a more invasive and motile phenotype has already 
been established in in vitro models but what is less well understood is how 
deregulation of angiogenesis may play a role in resistant disease.  
Deregulation of growth factor receptor expression and activation in acquired 
anti-oestrogen resistance has been clearly demonstrated (Knowlden et al., 
2003; Massarweh et al., 2008) and provides growth signalling in the presence of 
endocrine agents. Here, we took a panel of breast cancer cell lines that 
represent different forms of anti-oestrogen resistance and examined whether 
angiogenic factors were also altered. Importantly, we were looking for factors 
that fit specific criteria. This would ensure that we took forward the best possible 
candidates for further investigations.  
Our criteria demanded that the “ideal” candidate factors would be;  
1. Upregulated, pro-angiogenic factors. Deregulation of angiogenesis 
that leads to increased endothelial cell growth and increased 
vascularisation could manifest as a result of increased pro-angiogenic 
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signalling or reduced anti-angiogenic signalling. We ultimately sought to 
reverse any changes that would bring about a pro-angiogenic phenotype 
and this would be much more straightforward through inhibition of pro-
angiogenic factors than it would be to increase the expression or activity 
of anti-angiogenic factors. In addition, this would prove more beneficial in 
identifying a druggable target with clinical relevance. 
2. Well established in the literature. Having determined factors that play a 
role in pro-angiogenic signalling we sought to explore the mechanism by 
which this deregulation came about. Selecting factors that are well-
documented and whose mechanism is well understood would facilitate 
this process.  
3. Druggable Targets. As mentioned, we wanted to explore reversal of 
pro-angiogenic signalling and so, choosing factors that are easily 
druggable or have commercially available inhibitors would enable this. 
4. Possess an established link with Src and FAK. Having established the 
importance of pro-invasive kinases Src and FAK in our cell models of 
endocrine resistance, and the documented link between these factors 
and angiogenesis (Eliceiri et al., 2002; Lin et al., 2003) we hypothesised 
that these factors may play a role in altered pro-angiogenic signalling. 
We therefore favoured pro-angiogenic factors that are regulated by these 
kinases.  
All three models of resistance demonstrated deregulation of pro- and anti-
angiogenic factors. TamR vs. MCF7wt cells and FasR vs. MCF7wt cells both 
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showed significant upregulation of commonly reported pro-angiogenic factors 
including the pro-angiogenic chemokine, IL-8 and the potent angiogenic growth 
factor, VEGF, both of which fit our criteria for factor selection. MCF7-X cells also 
demonstrated significant upregulation of VEGF; however, this was 
accompanied by an increased expression of several anti-angiogenic agents 
including Thrombospondin 1. 
IL-8 is a pleiotropic chemokine expressed in a variety of tissues including colon, 
lung and prostate which is also expressed by endothelial cells where it functions 
in promotion of metastasis and angiogenesis (Keping, 2001). IL-8 has 
previously been shown to bind to CXCR1 and CXCR2 receptors and promote 
proliferation and survival signalling in endothelial cells (Li et al., 2003). The 
expression of this chemokine has also been shown to be elevated in breast 
cancer tumours that do not express ER (Freund et al., 2002) which may 
contribute to an invasive phenotype in cancer cells (Green et al., 1997).  
VEGF-A is the most important VEGF family member in promotion of 
angiogenesis. VEGF-C predominantly functions in lymphangiogenesis, or 
development of new lymphatic vessels (Stacker et al., 2002). For our purposes, 
therefore, VEGF-A is of greater importance and in this work is commonly 
referred to as VEGF. VEGF exerts its effect primarily by binding to VEGFR2 on 
the cell surface of endothelial cells resulting in proliferation and vascularisation 
of the surrounding tissue (Adams et al., 2000). VEGF mRNA and protein 
expression has already been shown to be elevated in in vivo MCF7wt cells after 
treatment with tamoxifen (Bogin et al., 2002) and additionally, to be regulated by 
the action of oestrogen, through binding of ER-α and c-Myc to VEGF promoter 
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sites. Our data, however, suggests than in our MCF7wt cell model short-term 
treatment with tamoxifen did not increase the protein expression of VEGF as 
measured by ELISA of conditioned media from these cells. Differences in our 
experimental procedure may explain the disparity in our results. Our studies 
were carried out using a 4 day treatment in comparison to the previous study in 
which cells were treated for 14 days. Additionally, Bogin et al. used MCF7wt 
cells growing as subcutaneous xenografts while we used in vitro MCF7wt cells. 
PCR analysis of IL-8 and VEGF expression in our panel of breast cancer cell 
lines (Figure 3.5) confirmed that the mRNA levels for these ligands in our 
acquired tamoxifen resistant breast cancer cell model is indeed elevated 
compared to the MCF7wt cells. Although, IL-8 can enhance the survival and 
proliferation of both tumour cells and endothelial cells, IL-8 failed to induce 
HUVEC cell growth. Moreover, we found that we could not detect the 
expression of CXCR receptors in our two endothelial cell models (data not 
shown). This is supported by similar work which suggests a role for IL-8 as an 
indirect mediator of angiogenesis that may work with a cohort of other factors to 
produce an angiogenic response (Petzelbauer et al., 1995). For this reason, we 
eliminated IL-8 from our study and continued with VEGF as a candidate 
mediator of a proangiogenic phenotype in acquired tamoxifen resistant breast 
cancer.  
Data from mRNA analysis was supported by protein analysis of VEGF 
expression by ELISA (Figure 3.8) which demonstrated that conditioned media 
taken from TamR cells had significantly higher concentrations of VEGF than 
MCF7wt media. However, elevated VEGF concentrations were not observed in 
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conditioned media taken from FasR, X-Cell or T47D cells and in addition, these 
cells lines did not significantly induce endothelial cell growth (Chapter 4) as a 
result of this we eliminated these cell lines from further investigations. 
3.4.2 Mechanism of VEGF Production in Breast Cancer Cells 
Having identified VEGF as a potential pro-angiogenic candidate associated with 
acquired tamoxifen resistance, we sought to explore the mechanism by which 
VEGF ligand was increased in TamR cells.  
3.4.2.1 Classical Regulation of VEGF Production: HIF-1α 
Angiogenesis is stimulated in response to low concentrations of oxygen through 
the action of HIF-1α. In normoxic conditions, the alpha subunits of this protein 
are hydroxylated by proline-hydroxylases, the function of which is limited by 
oxygen concentration. The effect of HIF-1α hydroxylation is subsequent 
ubiquitination of the protein by VHL E3 ubiquitin ligase enzymes followed by 
degradation by the proteasome. In a hypoxic environment the action of the 
proline-hydroxylase enzyme is inhibited and so, HIF is free to upregulate the 
expression of target genes (Huang et al., 1998). HIF-1 alpha binds to response 
elements upstream of genes not only implicated in angiogenesis, such as 
VEGF, but in tumour progression by mediating cell proliferation and survival 
(iNOS, IGF2) (Laughner et al., 2001).  
Here, however, we present data that suggests that although HIF-1 alpha is 
detectable at both mRNA and protein levels in both the endocrine-sensitive 
MCF7wt and the anti-oestrogen resistant TamR cells, there is no significant 
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difference seen between them in contrast to VEGF, which is greatly upregulated 
in TamR cells. Lack of correlation between HIF-1α expression/activity and 
VEGF protein expression suggests a HIF-1α independent mechanism. Previous 
work supports a model in which angiogenic signalling through increased VEGF 
production can continue in the absence of altered HIF-1α signalling.  
It has been proposed that although loss of HIF-1α in tumour cells does indeed 
limit tumour growth, it does not eliminate the tumour and growth may eventually 
resume in an HIF-1α independent manner (Sutphin et al., 2004). In colon 
cancer cells, induction of mutant variants of HIF-1α by RNA interference did not 
completely eliminate VEGF production (Mizukami et al., 2004). The same group 
also found that after the knock-down of HIF-1 alpha, the expression of the 
chemokine IL-8 was increased under hypoxic conditions and that inhibition of 
IL-8 reduced the hypoxic stimulation of VEGF production (Mizukami et al., 
2005). A study in which siRNA was used to knock-down the expression of HIF-
1α in a hepatocellular carcinoma cell line found detectable levels of VEGF 
production that could be further reduced using inhibitors that targeted Akt/PI3K 
and the transcription factor SP1 (Sae Byeol Choi, 2011). In exploring HIF-1α 
independent mechanisms relevant to our own cell models we then sought to 
explore VEGF regulation in endocrine-resistant cells based on signalling 
through the well-documented receptor implicated in endocrine resistance, the 
ER itself.  
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3.4.2.2 HIF-1α Independent Regulation of VEGF Production: ER 
Previous evidence linking ER to the regulation of VEGF supports the hypothesis 
that alterations in ER signalling as a result of endocrine resistance could alter 
VEGF production by tumour cells. Pre-clinical evidence suggested that VEGF 
transcription may be regulated by oestrogen activity through ERα via SP-
proteins (Stoner et al., 2004), and that VEGF regulation may be controlled by a 
complex ERα-ERβ mechanism which alters the effect of E2 binding (Buteau-
Lozano et al., 2002).  
Clinically, increased circulating VEGF levels have been reported in tamoxifen 
treated patients with metastatic disease compared to those not receiving 
tamoxifen, which may illustrate a deregulation of VEGF production as a result of 
treatment with tamoxifen (Adams et al., 2000). Having established a rationale 
for examining ER regulation of VEGF, we analysed the production of VEGF by 
MCF7wt and TamR cells that had been treated for 96-hours with oestradiol 
stimulation, tamoxifen inhibition or fulvestrant inhibition. However, as Figure 
3.11 illustrates, no treatment group showed a significant difference in VEGF 
levels when compared to control. Although we are not the first to suggest that 
ER may not play a role in regulation of VEGF in these cell lines (Bogin et al., 
2002; Guo et al., 2003; Hyder et al., 1998), it must be taken into consideration 
that the use of short-term stimulation or inhibition may not be sufficient to 
produce alterations in VEGF production and that longer term treatment may be 
required. Having found no correlation between ER activity and the production of 
increased VEGF by endocrine-resistant cells, we explored the involvement of 
Src kinases. These pro-invasive enzymes are known to be deregulated in 
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tamoxifen resistance in vitro and have been previously implicated in the 
regulation of VEGF in the literature (Eliceiri et al., 1999; Hiscox et al., 2006b).  
3.4.2.3 HIF-1α Independent Regulation of VEGF Production: Src 
Kinase 
On examination of Src kinase inhibition as well as In Figure 3.12, data illustrates 
that TamR cells exhibit a higher activity of the intracellular signalling molecules 
MAPK and Akt as well as increased Src kinase activity. As discussed 
previously, alterations in signalling through these second messenger hubs can 
result in altered transcription and expression of pro-angiogenic signalling 
molecules such as VEGF. When we examined what effect inhibition of these 
proteins had on the concentration of VEGF in conditioned media taken from 
TamR cells we found that only inhibition of Src kinase resulted in reduced 
VEGF (Figure 3.13) 
Signalling through MAPK has been shown to directly upregulate expression of 
VEGF by directly phosphorylating the alpha subunit of HIF-1 and increasing 
transcriptional activity of the protein. Akt signalling on the other hand also 
increases VEGF expression by binding HIF-1 alpha, however, the mechanism is 
slightly different in that Akt stabilises the protein binding of HIF-1 alpha to the 
HRE (Sodhi et al., 2001). Thus both MAPK and Akt can independently regulate 
the activity of HIF-1 alpha. However, in our study we have demonstrated that 
inhibition of these kinases did not reduce VEGF production by TamR cells 
which may support the hypothesis that the increases seen in VEGF 
concentration in TamR conditioned media versus MCF7wt conditioned media 
are not as a result of elevated MAPK or Akt signalling.  
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Inhibition of Src kinase, however, resulted in a significant reduction in the VEGF 
concentration in TamR conditioned media. This would suggest that the 
increases seen in TamR CM versus MCF7wt CM are the result of alterations in 
signalling through Src kinase and it is this change that mediate increases in 
VEGF expression. Regulation of angiogenesis by the Src family kinases has not 
been a huge subject of interest; however, the evidence that already exists 
demonstrates that Src plays a vital role in the regulation of endothelial cell 
function and angiogenesis. Src null mice exhibit normal vascular system 
development; however, mice deficient in Src, Fyn and Yes do not survive past 
approximately 10 days, which is the same time period that VEGFR null mice 
undergo embryonic lethality (Donald et al., 2005). The role of Src in VEGF 
regulation is usually attributed to its ability to increase VEGF mRNA production 
by binding to HIF-1 alpha and STAT3 at the VEGF promoter region, therefore 
increasing its expression (Gray et al., 2005).  
3.5 Chapter Summary  
In this chapter, we have shown that;  
- MCF7wt models of acquired tamoxifen resistance and fulvestrant 
resistance overexpress genes for a number of key positive regulators of 
angiogenesis 
- VEGF protein expression is significantly increased in TamR cells which 
reflects changes seen in gene expression 
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- Alterations seen in VEGF expression do not appear to be due to deregulation 
of HIF 1-alpha expression or signalling through the ER but rather arise as a 
consequence of increased Src activity in these cells 
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Chapter 4: In vitro Assessment of Conditioned Media Effects on 
Endothelial Cell Function 
4.1 Introduction 
Having established that key pro-angiogenic factors are deregulated in 
endocrine-resistant breast cancer cell models, the next element of this project 
was to study whether this translated into an increased capacity to promote 
angiogenic events in endothelial cells. Two cells lines were used to model 
endothelial cell function: HUVEC and HECV.  
Human umbilical vein endothelial cells (HUVECs) are a primary cell line that are 
isolated from cultures of mixed umbilical cord vein cells before fibroblasts and 
other non-endothelial cell are removed by centrifugation and enzyme action. 
They are typically used between passages 8 and 10 to maintain primary cell 
characteristics (Rhim et al., 1998).  
Although a good model of endothelial cells, the HUVEC cell line can be 
challenging to use in vitro due to their passage limitations. To address this, and 
also to limit cell line specific effects, we sought to use an alternative model of 
endothelial cells, namely, the HECV cell line. These are primary endothelial 
cells that are more suitable for continuous culture and retain primary cell 
characteristics for longer, allowing them to be maintained in cell culture for ~15 
passages.  
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4.2 Results 
4.2.1 Effect of Breast Cancer Cell Line Conditioned Media on 
Endothelial Cell Proliferation  
The ability of breast cancer conditioned media to promote the proliferation of 
endothelial cells was determined by MTS assay. Endothelial cells (HUVEC and 
HECV) were grown to 70% confluency being treated for 72 hours with 
conditioned media after which an MTS assay was performed to assess 
proliferation.  
All breast cancer cell types induced HUVEC proliferation (Figure 4.1 A) but a 
significant increase was only observed in endothelial cells treated with TamR 
conditioned media. These growth effects were also shown in HECV cells 
(Figure 4.1 B) again illustrating that TamR conditioned media increases 
endothelial cell proliferation to a greater extent versus other cell lines.  
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Figure 4.1 Effect of conditioned media from several breast cancer cell lines on 
the proliferation of HUVEC and HECV endothelial cells as determined by MTS 
assay.   
HUVEC and HECV cells were seeded onto 96-well plates in basal media and grown to 70% confluency before 
being quiesced in serum free media for 24 hours. Media were then replaced with neat conditioned media from 
breast cancer cell lines (MCF7wt, TamR, FasR, T47D, and MCF7-X) or an untreated media as control. Cell 
proliferation was assessed using MTS reagent. Data are presented as % Control ± SEM (* p<0.05 vs. Control, 
n=3) 
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4.2.2 Blockage of Endothelial Cell VEGFR2 Attenuates their 
Response to TamR Conditioned Media 
Having determined that only TamR conditioned media significantly increased 
cell proliferation versus MCF7wt conditioned media; it was taken forward for 
further investigations. Endothelial cells respond to stimulation with VEGF which 
has previously been shown to be upregulated in TamR cells versus endocrine-
sensitive cells. Therefore we wished to further investigate whether VEGF 
receptors represent a major factor for TamR conditioned media induced 
endothelial cell proliferation.  
To examine this, HUVEC cells were pre-treated with the small molecule inhibitor 
ZM323881 to block signalling through the VEGFR2 receptor, as this receptor 
mediates most of the pro-angiogenic effects of VEGF. As illustrated in Figure 
4.2, this pre-treatment blocked the capacity of TamR conditioned media to 
induce cell proliferation of both HUEVC and HECV cell lines.  
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Figure 4.2 Cell proliferation of endothelial cells after treatment with conditioned 
media from TamR cell lines, ± the VEGFR2 inhibitor ZM323881   
HUVEC and HECV cells were seeded onto 96-well plates in basal media and grown to 70% 
confluency before being quiesced in serum free media for 24 hours. Following this, media were 
removed and endothelial cells were treated with w&5 containing 1µM ZM323881 or a w&5 
control. After 1 hour of treatment with the inhibitor, media were once again removed and 
replaced with conditioned media from TamR cells. Cell proliferation was assessed using MTS 
reagent. Data are presented as % Control ± SEM (* p<0.05 vs. w&5 Control, *** p<0.0001 vs. 
TamR CM control, n=3) 
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4.2.3 Reductions in VEGF Concentration by Src kinase Inhibition 
Result in Reduction of Cell Proliferation by TamR Conditioned Media  
Previous data in this project has suggested that VEGF production is regulated 
by Src kinase. Therefore, Src may represent a target with which to reduce the 
angiogenic capacity of TamR conditioned media. To investigate this, TamR 
cells were treated with the Src-inhibitor, AZD0530, prior to collection of 
conditioned media for endothelial cell growth assays. Conditioned media from 
Src-inhibited TamR cells failed to induce growth of endothelial cells to the same 
extent as untreated TamR conditioned media (Figure 4.3).  
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Figure 4.3 Cell proliferation of endothelial cells after treatment with conditioned 
media from TamR cells, ± the Src kinase inhibitor, Saracatinib   
HUVEC and HECV cells were seeded onto 96-well plates in basal media and grown to 70% confluency before 
being quiesced in serum free media for 24 hours. Following this, media were removed and endothelial cells were 
treated with TamR conditioned media pre-treated with 1µM Saracatinib or TamR conditioned media control. After 
72 hours cell proliferation was assessed using MTS reagent. Data are presented as % Control ± SEM (* p<0.05 
vs. w&5 Control, *** p<0.0001 vs. TamR CM control, n=3) 
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4.2.4 TamR Conditioned Media Promotes VEGF Signalling in 
Endothelial Cells  
Pro-angiogenic signalling through VEGF relies on the ligand binding its 
receptor, primarily VEGFR2, on endothelial cells. This activates signalling 
through Src/PI3K, leading to cell survival, and MAPK, signalling resulting in cell 
proliferation. Through Western blot analysis, endothelial cell signalling was 
examined in the presence of conditioned media with or without pre-treatment 
with the Src kinase inhibitor saracatinib.  
Analysis of phosphorylation of HUVEC and HECV VEGFR2 (Figures 4.4 and 
4.7) after stimulation with MCF7wt and TamR conditioned media illustrated that 
TamR conditioned media increases the phosphorylation of VEGFR2 to a 
greater extent than MCF7wt CM. Conditioned media from TamR cells that had 
been pre-treated with the Src inhibitor, however, had a reduced capacity to 
activate VEGFR2. TamR conditioned media also increased the activity of 
VEGFR2 related downstream signalling molecules in HUVECs and HECVs 
(Figures 4.5 and 4.8). Akt, Src and MAPK were all found to be phosphorylated 
to a greater extent in cells treated with TamR conditioned media than in cells 
treated with MCF7wt media. Finally, Src inhibition in TamR cells resulted in 
reduced phosphorylation of downstream signalling molecules in HUVECs and 
HECVs when stimulated with conditioned media from drugged cells (Figures 4.6 
and 4.9).  
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Figure 4.4 Effect of MCF7wt and TamR conditioned media treatment on activation 
of VEGFR2 in HUVEC cells and the effect of TamR Src kinase inhibition on TamR 
conditioned media activation of pVEGFR2 
HUVEC cells were seeded onto 12-well plates in basal media and grown to 70% confluency before being 
quiesced in serum free media for 24 hours. Following this, media were removed and endothelial cells were 
treated with conditioned media or conditioned media from cells that had been pre-treated with Saracatinib. Cells 
were lysed as described in materials and methods (Section 2.5). Total soluble protein (20µg) was subjected to 
SDS-PAGE/Western blot analysis and the membranes were probed with antibodies specific to VEFGR2. 
Densitometry was carried on bands obtained and results were corrected for loading using GAPDH, presented as 
% Control ± SEM (** p<0.01 vs. Control, *** p<0.001, n=3) 
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Figure 4.5 Effect of MCF7wt and TamR conditioned media treatment on signalling 
through Akt, Src and MAPK in HUVECs 
HUVEC cells were seeded onto 12-well plates in basal media and grown to 70% confluency before being 
quiesced in serum free media for 24 hours. Following this, media were removed and endothelial cells were 
treated with conditioned media. Cells were lysed as described in materials and methods (Section 2.5). Total 
soluble protein (20µg) was subjected to SDS-PAGE/Western blot analysis and the membranes were probed with 
antibodies specific to Akt, Src and MAPK. Densitometry was carried on bands obtained and results were 
corrected for loading using GAPDH, presented as % Control ± SEM (* p<0.05 vs. Control, ** p<0.01, n=3) 
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Figure 4.6 Effect of TamR Src kinase inhibition on TamR conditioned media 
activation of HUVEC pAkt, pSrc and pMAPK 
HUVEC cells were seeded onto 12-well plates in basal media and grown to 70% confluency before being 
quiesced in serum free media for 24 hours. Following this, media were removed and endothelial cells were 
treated with conditioned media or conditioned media from cells that had been pre-treated with Saracatinib. Cells 
were lysed as described in materials and methods (Section 2.5). Total soluble protein (20µg) was subjected to 
SDS-PAGE/Western blot analysis and the membranes were probed with antibodies specific to Akt, Src and 
MAPK. Densitometry was carried on bands obtained and results were corrected for loading using GAPDH, 
presented as % Control ± SEM (* p<0.05 vs. Control, ** p<0.01 vs. Control, *** p<0.001 vs. Control n=3) 
118 
 
 
Figure 4.7 Effect of MCF7wt and TamR conditioned media treatment on activation 
of VEGFR2 in HECV cells and the effect of TamR Src kinase inhibition on TamR 
conditioned media activation of pVEGFR2 
HECV cells were seeded onto 12-well plates in basal media and grown to 70% confluency before being quiesced 
in serum free media for 24 hours. Following this, media were removed and endothelial cells were treated with 
conditioned media or conditioned media from cells that had been pre-treated with Saracatinib. Cells were lysed 
as described in materials and methods (Section 2.5). Total soluble protein (20µg) was subjected to SDS-
PAGE/Western blot analysis and the membranes were probed with antibodies specific to VEFGR2. Densitometry 
was carried on bands obtained and results were corrected for loading using GAPDH, presented as % Control ± 
SEM (** p<0.01 vs. Control, *** p<0.001, n=3) 
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Figure 4.8 Effect of MCF7wt and TamR conditioned media treatment on signalling 
through Akt, Src and MAPK in HECVs 
HECV cells were seeded onto 12-well plates in basal media and grown to 70% confluency before being quiesced 
in serum free media for 24 hours. Following this, media were removed and endothelial cells were treated with 
conditioned media. Cells were lysed as described in materials and methods (Section 2.5). Total soluble protein 
(20µg) was subjected to SDS-PAGE/Western blot analysis and the membranes were probed with antibodies 
specific to Akt, Src and MAPK. Densitometry was carried on bands obtained and results were corrected for 
loading using GAPDH, presented as % Control ± SEM (* p<0.05 vs. Control, ** p<0.01, n=3) 
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Figure 4.9 Effect of TamR Src kinase inhibition on TamR conditioned media 
activation of HECV pAkt, pSrc and pMAPK 
HECV cells were seeded onto 12-well plates in basal media and grown to 70% confluency before being quiesced 
in serum free media for 24 hours. Following this, media were removed and endothelial cells were treated with 
conditioned media or conditioned media from cells that had been pre-treated with Saracatinib. Cells were lysed 
as described in materials and methods (Section 2.5). Total soluble protein (20µg) was subjected to SDS-
PAGE/Western blot analysis and the membranes were probed with antibodies specific to Akt, Src and MAPK. 
Densitometry was carried on bands obtained and results were corrected for loading using GAPDH, presented as 
% Control ± SEM (* p<0.05 vs. Control, ** p<0.01 vs. Control, *** p<0.001 vs. Control n=3) 
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4.2.5 TamR Conditioned Media Increases the Migratory Capacity of 
Endothelial Cells to a Greater Extent than that of MCF7wt Media  
Migration of endothelial cells has been shown to play an essential role in the 
process of angiogenesis. To examine the effect of paracrine signalling from 
breast cancer cells on the migratory capacity of endothelial cells, we carried out 
two tests of migration using our in vivo endothelial cell lines. Wound healing 
assays carried out illustrated that the capacity of endothelial cells to close over 
an area created on a super-confluent monolayer of cells is increased in the 
presence of conditioned media from TamR cells. Data in Figure 4.10 and 4.11 
illustrate similar responses in both HUVEC and HECV cell lines.  
Migration was also assessed using a Boyden chamber cell culture system in 
which conditioned media was held in the 24-well plate under the chamber and 
endothelial cells were seeded into the chamber itself. Cell counts of cells that 
had migrated through the filter towards the conditioned media were found to be 
higher when the conditioned media was taken from TamR cells (Figure 4.12 
and 4.13).  
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Figure 4.10 Migratory capacities of HUVECs after stimulation with conditioned 
media taken from MCF7wt and TamR cell lines as measured by wounding assay 
HUVEC cells were seeded onto 12-well plates in basal media and grown to 100% confluency before a 1cm line 
of cells is removed using a pipette tip and aspirator. Following this, media were removed and endothelial cells 
were treated with MCF7wt or TamR conditioned media. After 24 hours cell migration was assessed by light 
microscope photography and image analysis using ImageJ software. Data are presented as % Control distance 
closed ± SEM (*** p<0.001 vs. Control, n=3) 
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Figure 4.11 Migratory capacities of HECVs after stimulation with conditioned 
media taken from MCF7wt and TamR cell lines as measured by wounding assay 
HECV cells were seeded onto 12-well plates in basal media and grown to 100% confluency before a 1cm line of 
cells is removed using a pipette tip and aspirator. Following this, media were removed and endothelial cells were 
treated with MCF7wt or TamR conditioned media. After 24 hours cell migration was assessed by light 
microscope photography and image analysis using ImageJ software. Data are presented as % Control distance 
closed ± SEM (*** p<0.001 vs. Control, n=3) 
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Figure 4.12 Migratory capacities of HUVECs after stimulation with conditioned 
media taken from MCF7wt and TamR cell lines as measured by Boyden chamber 
assay 
HUVEC cells were seeded into Boyden chambers in w&5. Wells below Boyden chambers had 100µl of 
conditioned media pipetted into each. After 24 hours cell migration was assessed by light microscope 
photography on formalin fixed and crystal violet stained filter membranes from each Boyden chamber. Image 
analysis was carried out using ImageJ software. Data are presented as % Control cells counted ± SEM (*p<0.05, 
** p<0.01 vs. Control, n=3) 
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Figure 4.13 Migratory capacities of HECVs after stimulation with conditioned 
media taken from MCF7wt and TamR cell lines as measured by Boyden chamber 
assay 
HECV cells were seeded into Boyden chambers in w&5. Wells below Boyden chambers had 100µl of conditioned 
media pipetted into each. After 24 hours cell migration was assessed by light microscope photography on 
formalin fixed and crystal violet stained filter membranes from each Boyden chamber. Image analysis was 
carried out using ImageJ software. Data are presented as % Control cells counted ± SEM (*p<0.05, ** p<0.01 vs. 
Control, n=3) 
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4.2.6 TamR Conditioned Media Increases the Tubule Formation of 
HUVECs 
Tubule formation accompanying proliferation of endothelial cells is indicative of 
a more complete angiogenic process. Endothelial cells that solely proliferate 
would not be capable of producing novel vasculature. For our work, this 
presents another method of screening pro- and anti-angiogenic factors. In our 
experiments, we grew endothelial cells on a Matrigel basement membrane in 
the presence of conditioned media to assess whether it would promote or inhibit 
the formation of endothelial cell tubules. It was found that only HUVEC cells 
demonstrated a capacity to form tubules when cultured on basement 
membranes. HECV cells, under control conditions, did not demonstrate 
quantifiable tubule formation and so, were excluded from this experiment. Data 
in Figure 4.14 illustrate that HUVECs, when stimulated with conditioned media 
from TamR cells, possess a greater capacity to form these two-dimensional 
tube like structures.  
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Figure 4.14 Tubule formation of HUVEC cells on Matrigel after stimulation with 
conditioned media taken from MCF7wt and TamR cell lines 
HUVEC cells were seeded onto 24-well plates, coated with Matrigel, in conditioned media. After 6 hours tubule 
formation was assessed by light microscope photography on formalin fixed tubules. Image analysis was carried 
out using ImageJ software. Data are presented as % Control cells counted ± SEM (*p<0.05, ** p<0.01 vs. 
Control, n=3) 
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4.2.7 HECV Cell Monolayers Lose Tight Junction Integrity after 
Treatment with TamR Conditioned Media  
The impedance of current flow across a monolayer of endothelial cells can be 
used to examine the integrity of tight junctions between the cells. In the 
presence of lowered integrity at tight junctions, a drop in the impedance of 
current can be measured and so, we can use various treatments to assess how 
different factors can illicit this effect. Initial attempts at using HUVEC cells for 
these experiments demonstrated that they did not form sufficient monolayers to 
continue using in ECIS investigations. In our experiments, a monolayer of 
HECV cells was treated with conditioned media from MCF7wt and TamR cell 
lines to observe whether this would have any effect on transendothelial 
electrical resistance (TER). Although this experiment was carried out in triplicate 
to establish significance, there was a large amount of variability in the data and 
so no significance could be drawn from the assay. Figure 4.15 shows a 
representative graph of TER over time after the addition of conditioned media 
from MFC7wt and TamR cell lines. Treatment with both conditioned media 
resulted in a drop in TER over time. Interestingly, TamR conditioned media 
produced a greater drop in TER.  
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Figure 4.15 Electrical impedance across a monolayer of HECV cells after 
treatment with conditioned media from MCF7wt and TamR cell lines 
HECV cells were seeded into 8W1E ECIS array plates in w&5 at sufficient number to produce a cell monolayer. 
ECIS analysis was begun and at 24 hours conditioned media were added to array wells. Data were analysed 
using proprietary ECIS software from which a graphical representation of TER over time could be drawn.  
 
 
 
130 
 
4.3 Discussion 
4.3.1 Conditioned Media from TamR is Capable of Stimulation 
Endothelial Cell Proliferation through a VEGF/VEGFR2 Dependant 
Mechanism  
The use of conditioned media to investigate paracrine stimulation between 
heterogeneous cell types is widely reported (Freshney, 2010). Previous 
observations from the Breast Cancer Molecular Pharmacology group have 
shown that fibroblast conditioned media is able to stimulate the migratory 
capacity of endocrine-resistant breast cancer cells, but it is not known whether 
these breast cancer cells are able to exact stimulatory effects on other cell 
types (Hiscox et al., 2006a). In this project we have sought to determine their 
effects on endothelial cell function and thus explore their pro-angiogenic 
capacity.  
The ability of TamR conditioned media to induce endothelial cell proliferation 
could arise as a result of the presence of several growth factors in the media 
secreted by these cells. Breast cancer cells have been shown to be capable of 
production of factors like TGF-α, VEGF, bFGF and PDGF (Ciardiello et al., 
2001; Rozengurt et al., 1985), however, our work using microarray and PCR 
techniques had shown that our TamR conditioned media possessed high levels 
of VEGF, a key mediator of endothelial cell proliferation.  
To determine whether VEGF was a central mediator of the proliferative 
response seen in HUVEC cells on treatment with TamR conditioned medium as 
opposed to other growth factors, we performed stimulation experiments on 
HUVEC cells with TamR conditioned media in the presence of absence of the 
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small molecule VEGFR2 receptor inhibitor (ZM323881). Within the VEGFR 
family of receptors, VEGFR2 has been shown to possess most of the 
proangiogenic function with VEGFR1 being required for haematopoietic stem 
cell recruitment and VEGFR3 regulating lymphatic endothelial cell function 
(Holmes et al., 2007). The necessity of VEGFR2 for mediating the proliferative 
effects of VEGF has been demonstrated in knockout studies where suppression 
of VEGFR2 expression results in reduced VEGF sensitivity in contrast to 
knockout of VEGFR1, where cells retain their response to VEGF (Koolwijk et 
al., 2001). Stimulation of VEGFR2 results in activation of the PI3K/AKT 
signalling pathway leading to a reduction in apoptotic signalling in endothelial 
cells (Fujio et al., 1999) as well as pro-angiogenic responses mediated through 
nitric oxide signalling, which results in endothelial cell proliferation and migration 
(Kawasaki et al., 2003). VEGFR2 activation also results in signal transduction 
through the MAPK pathway (Cross et al., 2003) where activated MAPK can 
promote proliferation in a c-Jun/c-Fos-dependant manner (Takahashi et al., 
1999). Indeed, recent data point to the MAPK pathway as a key regulator of 
endothelial cell response to angiogenic ligands with deletion of Erk1 or Erk2 
resulting in reduced cell proliferation and migration (Srinivasan et al., 2009). Our 
data suggest that endothelial cells treated with TamR conditioned media 
demonstrate increased activity through these second messengers. Data from 
VEGF stimulation of endothelial cells also demonstrated this elevated signalling 
likely as a consequence of VEGF binding VEGFR2. 
The selective VEGFR2 inhibitor ZM323881 has been demonstrated to reduce 
VEGF-stimulated endothelial cell proliferation in vitro and has an IC50 of 8nM 
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(Whittles et al., 2002). In our experiments, we found that pre-treatment of 
endothelial cells for 1 hour with 0.5nM of the inhibitor before stimulating with 
conditioned media from TamR cells reduced the capability of TamR conditioned 
media to induce endothelial cell proliferation. Dose-response studies of 
endothelial cells to the inhibitor alone revealed that cell proliferation of both 
HUVEC and HECV cells was not significantly reduced up to 10µM of 
ZM323881.  
These inhibitor studies suggest that VEGF present in TamR conditioned media 
is responsible for induction of endothelial cell proliferation via activation of 
VEGFR2. Having established the importance of the VEGF/VEGFR2 axis in 
mediating increased endothelial cell growth and suggesting that this increased 
VEGF concentration is produced by a Src dependant manner, we then sought 
to determine the effect of Src kinase inhibition on VEGF production by TamR 
cells.  
4.3.2. Inhibition of Src Kinase in TamR Cells Attenuated their Ability 
to Promote Endothelial Cell Growth 
Increased phosphorylation of VEGFR2 by TamR conditioned media as a result 
of elevated VEGF is indicative of increased pro-angiogenic signalling in 
endothelial cells. Inhibition of Src kinase signalling in TamR cells using the 
small molecule inhibitor saracatinib illustrated that, while TamR conditioned 
media can increase the phosphorylation of VEGFR2, the inhibition of Src kinase 
in TamR cells prior to collection of conditioned media is capable of reducing 
phosphorylation of the receptor, likely as a result of decreased VEGF ligand 
concentration in the media. We have demonstrated this effect in both primary 
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endothelial cell models with similar patterns of phosphorylation exhibited by 
both HUVEC and HECV cell lines. Additionally, stimulation of endothelial cells 
with conditioned media from Src inhibitor treated TamR cells results in 
decreased Akt, Src and MAPK phosphorylation than when endothelial cells are 
stimulated with untreated TamR media.  
4.3.3 TamR Conditioned Media Increases the Migratory Capacity of 
Endothelial Cells 
The migration of endothelial cells is a well-documented step in the angiogenic 
process. Chemoattractant-mediated, pro-motile signalling from neighbouring 
cells promotes the migration of endothelial cells towards hypoxic areas and 
allows reestablishment of oxygenation to those tissues. VEGF stimulation of 
endothelial cells results in the formation of actin structures involved in the 
migration of cells (Lamalice et al., 2007). Filopodia orientate towards the higher 
concentration of chemoattractant while lamellipodia and stress fibres function in 
forward movement, adherence and contraction of the cell body (Small et al., 
2005). Increased signalling through heregulin (HRG) has been shown to 
increase the expression of VEGF by binding to HRG response elements 
upstream of VEGF promoter regions. In murine lung models, endothelial cell 
migration has been shown to increase on stimulation by HRG, as a result of 
subsequent VEGF expression. One group has generated data illustrating the 
increased production of heregulin by MCF7wt cells after stimulation with 
oestradiol (Keshamouni et al., 2002) however, it remains to be elucidated what 
effect tamoxifen stimulation and indeed development of tamoxifen resistance 
has on this process. In our experiments we show that TamR conditioned media 
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has a greater propensity to stimulate endothelial cell migration, as illustrated in 
the wound healing assay and as a chemoattractant as demonstrated in the 
Boyden chamber assay.  
A selection of Rho family small GTPases are thought to be involved in the 
response of endothelial cell migration to the activation of VEGFR2 by VEGF 
(Lamalice et al., 2007). In particular, Cdc42 is known to be a key regulator of 
cell polarity and directionality of membrane protrusions (Cau et al., 2005). In 
endothelial cells, Cdc42 on leading edge protrusions sense VEGF gradients as 
a result of VEGFR2 binding and subsequent activation of Cdc42 and stress 
activated protein kinases (SAPK/p38) which results in stress fibre remodelling 
(Lamalice et al., 2003). The high concentration of VEGF in conditioned media 
form TamR cells therefore, should be sufficient to activate VEGFR2 mediated 
migratory mechanisms and results in the observed increase in migratory 
capacity seen in the Boyden chamber and wound healing assay. Although it 
should be noted that in the wound healing assay, there is no discernible 
concentration gradient and so we must hypothesise that although we are seeing 
migration not proliferation (as evidenced by the closure of space in a short time 
period) it is not directional migration. Rather, the cells migrate into the available 
space in response to increased motile signalling on the leading (wound) edge 
and not the reverse, due to contact inhibition.  
4.3.4 TamR Conditioned Media Increases the Capacity of HUVEC 
Cells to Form Tube Like Structures  
The formation of tubule structures when grown on a basement membrane, such 
as fibronectin or Matrigel, is a component of endothelial cell behaviour. As such, 
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it is a relatively easy in vitro method for examining functional angiogenesis as 
opposed to solely measuring proliferation, which, although obviously tied to 
angiogenesis, the presence of uncontrolled growth alone without formation of 
tubule structures would not lead to increased vascularisation of tissue. Matrigel 
represents an artificial basement membrane construct and is produced in 
abundance by a murine tumour cell line, Engelbreth-Holm-Swarm (EHS) 
(Kleinman et al., 2005). Our HUVEC cell line exhibited visible tubule formation 
six hours after seeding onto Matrigel in its home media as well as in w&5 
control media and so these were used as positive controls in each assay. When 
treated with conditioned media, TamR cell media exhibited an increased 
capacity to form tubules than control media. MCF7wt media, however, did not 
greatly affect the tubule forming capacity of endothelial cells.  
The use of HUVEC cells is well established for use in tubule assays as well as 
several other endothelial cell models including SVEC4-10 (murine) and HMEC-
1 (human) (Arnaoutova et al., 2010). However, our HEVC cells, did not display 
successful tubule formation under control conditions in the assay. This is 
surprising given reports by Rmali et al. 2005 who successfully made use of 
tubule formation assay. Although, the same study put forward an hypothesis 
that loss of certain cell markers such as tumour endothelial marker 8 (TEM-8) 
results in an inability to form tubules in vitro (Rmali et al., 2005). Given the 
nature of continuous culture cells lines, it is not unlikely that some loss of 
expression of certain proteins may lead to losses in functionality. It would be 
worthwhile to examine HECV cells of different passage to determine whether 
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tubule formation could be observed at an earlier time point in their culture to 
elucidate whether a loss in functionality has occurred.  
4.3.5 Effects of TamR Conditioned Media May Reduce Cell-cell Tight 
Junction Integrity in Endothelial Cells 
Electric cell-substrate impedance sensing (ECIS) is a method of measuring the 
impedance of an electrical current across a monolayer of cells, in our case 
endothelial cells, which depends upon the insulator capacity of cells upon gold-
film electrodes. The movement of current around the cells can be used to 
determine changes in cell shape, which can be used to measure cellular growth 
and migration and also be used to assess tight junction formation and thus the 
integrity of intracellular contacts, an indirect indicator of monolayer permeability. 
This latter element is important as monolayer permeability has been implicated 
in tumour cell intravasation and thus haematogenous metastatic spread (Fidler 
et al., 2002) and has been shown to be driven by a VEGF and Src mediated 
mechanism (Criscuoli et al., 2005). Our protocol involved allowing endothelial 
layer monolayers to stabilise over 24 hours before challenging cells with 
conditioned media from MCF7wt and TamR cell lines. We observed a visible 
decrease in transendothelial resistance after treatment with both media when 
compared to w&5 control media. Despite these encouraging results, however, 
we found high variability within these results using the same protocol and 
conditions. As the use of ECIS equipment was not routine within our group it is 
possible that the inexperience of using this novel technique was a cause of the 
poor reproducibility. Further practice of this technique would clearly be 
invaluable as some of the results obtained would help explain whether TamR 
137 
 
cells are capable of modulating vascular permeability. However, despite this, 
the data did suggest that TamR conditioned media was able to reduce 
transendothelial permeability to a greater extent than endocrine-sensitive 
MCF7wt cells. The implications of this are interesting in that the ability of breast 
cancer cells to modulate intracellular communication and endothelial 
permeability may enhance their capacity to spread. 
4.4 Chapter Summary 
- Conditioned media from TamR cells has a greater capacity to induce 
endothelial cell proliferation than media taken from MCF7wt cells  
- TamR conditioned media increases signalling through VEGFR2 and second 
messenger systems in endothelial cells, however, this effect is reduced when 
the TamR cells had been previously treated with the Src kinase inhibitor 
Saracatinib 
 - Functional assessment of endothelial cells after stimulation with TamR 
conditioned media revealed that this treatment also increases the capacity of 
these cells to migrate and form tubules and may also increase vascular 
permeability by reducing the integrity of endothelial cell monolayers 
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Chapter 5 – Ex vivo and In vivo Analysis of Pro-angiogenic 
Capacity of TamR cells  
5.1 Introduction 
Data in the previous chapters, demonstrates that VEGF secretion is elevated in 
TamR cells and that this process involves Src kinase activity. Furthermore, 
conditioned media from TamR cells is able to promote angiogenic responses in 
two endothelial cell lines. However, despite this encouraging in vitro data, it still 
remains to be seen whether these effects translate into pro-angiogenic 
responses in a more clinically relevant context i.e. in vivo. Thus, the aims of this 
chapter were to assay the effects of TamR conditioned media on vascular 
development using the chick chorioallantoic membrane assay, to determine the 
effects of TamR conditioned media on tubule formation in a rat aortic ring assay 
and finally to determine whether there is altered vascularisation in TamR cell 
mouse xenografts when compared to MCF7wt xenografts.  
5.2 Results 
5.2.1 Chick Chorioallantoic Membrane (CAM) Assay  
The use of the chick chorioallantoic membrane assay in the study of 
angiogenesis has been a commonly utilised in vivo tool for nearly a hundred 
years with evidence of the assay being carried out as far back as 1913 (Ribatti, 
2004). The chorioallantois is the name given to the fusion product of the 
allantois, an extra-embryonic membrane in which blood vessels begin to form 
after three days incubation, and the chorion, which is the outermost membrane 
surrounding the embryo. Therefore, vessels within the chorioallantois function to 
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mediate gas exchange between the embryo and the environment through the 
porous shell.  
In our experiments we wanted to determine whether proangiogenic and 
chemoattractant properties displayed by endothelial cells in vitro following 
stimulation with conditioned media could also be demonstrated in an in vivo 
system. Sterilised filter papers soaked in conditioned media from either MCF7wt 
or TamR cells or untreated media as a control were used to approximate the 
effect of a body of tumour cells placed in close proximity to a vascular network 
(modelled by the developing vasculature of the CAM tissue). We hypothesised 
that the increased angiogenic factors known to be present in the conditioned 
media from TamR cells would promote vascular development and that this 
would be directed towards the filter paper containing TamR conditioned media. 
Disappointingly, however, this methodology proved technically challenging and 
we encountered difficulties with maintaining sufficient numbers of viable 
embryos in each experiment in order to correctly compare between treatment 
and controls. Figure 5.1 illustrates one successful experiment where TamR 
conditioned media appeared to promote development of vasculature within the 
CAM (arrowed).  
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Figure 5.1 Effect of TAMR conditioned media on the vessel development in chick 
embryos.  
Top, fertilised egg after some of the shell is removed during windowing and before treatment with filter papers. 
Bottom, development of vasculature at days 1, 2 and 3 post treatment. Fertilised chick eggs at day 1 post 
fertilisation were incubated at 37.5°C. At day 2 post fertilisation shells were opened to allow display of 
chorioallantoic membrane. Filter papers incubated in conditioned media from TamR cells overnight were placed 
on the CAM distal to the embryo. Photographs were taken at 24 hour intervals.  
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5.2.2 Rat Aortic Ring Assay  
The use of the aortic ring assay is considered to be a better representative of 
the in vivo environment versus 2D cultures of single cell types as the aorta 
consists of a number of cell types, representing both endothelial and non-
endothelial cells alike. Under the appropriate conditions, endothelial cells within 
the aorta will begin to proliferate and migrate in order to form tubules (Go et al., 
2003) which begin to stretch out into the surrounding matrix into which they 
have been implanted.  
Freshly removed rat aorta were sectioned into 1mm ringlets and inserted into 
Matrigel where they were then exposed to plain media or conditioned medium 
from either MCF7wt cells or their TAM resistant counterparts.  
Under control conditions (i.e. exposure to plain media), aortic endothelial cell 
growth was seen after 24 hours of culture, with tubule structures becoming 
more pronounced until day 5, after which it appeared that the cells did not 
proliferate any further.  
Aortic sections exposed to MCF7wt conditioned media displayed little, if any, 
outgrowth of endothelial cells. Rather, these treatments resulted in significant 
amounts of fibroblast infiltration of the Matrigel (Figure 5.2A). In contrast to this, 
TamR conditioned media appeared to promote the growth of large numbers of 
tubule-like structures within the Matrigel (Figure 5.2B).  
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Imaging was performed of the resultant structures to enable the quantitation of 
tubules; these data further demonstrated the contrasting effects of MCF7wt and 
TamR cell medium to promote aortic ring, endothelial cell tubule formation 
(Figure 5.2).  
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Figure 5.2 Effect of MCF7wt and TAMR conditioned media on the tubule 
formation of endothelial cells from rat aortic tissue grown on a Matrigel 
membrane.   
The descending thoracic aorta was dissected from three week old Sprague-Dawley rats. Tissues were debrided 
of adipose and fibrous tissues, washed in warm heparin containing wRPMI before being sectioned into 2mm 
ringlets. Following this, sections were placed onto Matrigel membranes in MCF7wt or TamR conditioned media. 
After 24 hours sections were photographed using light microscopy. Tubule formations were counted with data 
here presented as % Control tubule formation counts ± SEM (** p<0.001 vs. w&5 Control, *** p<0.0001 vs. 
MCF7wt, n=3) 
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5.2.3 MCF7 and TAMR Xenograft Studies 
Having observed that TamR conditioned media leads to an increased 
proliferation rates of endothelial cells in vivo, we hypothesised that TamR cells 
grown as xenografts would display a greater level of vascularisation than would 
their MCF7wt counterparts. We sought to determine whether this was the case 
by using tissue sections made available to us from mice which had 
subcutaneous xenografts from either MCF7wt or TamR cells. Once the 
xenografts were removed, fixed and sectioned, an antibody specific to the 
endothelial cell antigen CD31 was used to specifically stain the tumour 
vasculature. CD31 is appropriate for this purpose as it is known to be 
constitutively expressed on the surface of endothelial cells to a much higher 
degree versus other cell types likely to be present within the tumour e.g. 
immune cells, fibroblasts and the tumour cells themselves (Parums et al., 1990; 
Righi et al., 2003). Stained sections were visualised and groups of “small” or 
“large” CD31 positive structures were counted, where groups of cells that 
occupied more than 1mm2 were counted as “large vessels” and those that 
occupied less than 0.1mm2 were reported as “small vessels”.  
Examination of CD31-stained tissue sections revealed that TamR xenografts 
possessed higher numbers of both large and small vessels versus MCF7wt 
xenograft tissues (Figure 5.3).  
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Figure 5.3 Differences in CD31 endothelial cell staining of xenograft tissue from 
mice grafted with MCF7wt and TAMR cells 
Formalin fixed paraffin embedded xenograft tissue was prepared as discussed in Chapter 2. Antigen recovery 
was carried out using citrate buffer at pH 6 and heat via a pressure cooker for 2 minutes. 1/15 dilutions of rat 
anti-mouse CD31 antibody were applied overnight and following washes with PBS, goat anti-rat secondary was 
applied for 2 hours. Finally, DAB/H202 was applied for 10 minutes with subsequent haematoxylin counterstaining. 
CD31 staining was assessed using ImageJ software. Data are presented as % Control ± SEM (* p<0.05 vs. 
Control, n=3) 
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5.3 Discussion 
5.3.1 Chick Chorioallantoic Membrane Assay  
To further investigate the pro-angiogenic properties of breast cancer cell 
conditioned media in an in vivo context, we attempted to use the Chick 
Chorioallantoic Membrane (CAM) assay. This assay is well established and has 
been routinely used to explore regulation of angiogenesis in a more complex 
system compared to in vitro cell lines (Cavill et al., 2010; Kusaka et al., 1991; 
Ribatti et al., 1999).  
Unfortunately, there were significant problems with this assay, mainly arising 
from a very poor embryo viability (<20% survival, on average) resulting in very 
few usable eggs which frustratingly resulted in being unable to achieve a 
complete set of data with matching controls. 
Studies report that embryonic viability for CAM assays ranges widely between 
30% and 70% (Auerbach et al., 1974; Dohle et al., 2009). Many factors can 
influence this including time taken to transport eggs between farm and 
laboratory. Our supplier was located in Lincolnshire and, although they has 
been used routinely by other departments in Cardiff University (with reported 
success), transport of materials for these experiments over such long distances 
may lead to a reduction in viability. Factors that affect transport while in route 
can also reduce viability including extended periods outside of chilled or 
incubator environments and the conditions of transport i.e. agitation due to poor 
road conditions (Ponce et al., 2003). We also found that contamination 
remained a significant factor for reduced viability. Despite stringent 
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decontamination of equipment and sterile working conditions we still found 
evidence of contamination on eggs with exposed CAM tissue, particularly after 
day 5 in culture. The use of filter-paper disks to apply treatment to the CAM has 
been previously reported in several studies in the testing of pro- and anti-
angiogenic agents (Murugesan et al., 2007; Sahni et al., 2006). The major 
disadvantage of using filter paper is that the paper itself can act as an 
inflammatory stimulus and effect a change in the assessment of angiogenesis. 
As a result of poor embryo viability we were unable to obtain significant results 
from assays as most CAM experiments use a minimum of 12 embryos for each 
group including positive and negative controls. Since concluding the 
experimental stage of this thesis we have discovered alternative culture 
methodologies that may increase embryonic viability which could be utilised in 
future studies. However, despite these challenges, we were able to collate 
some data that pointed to an increased ability of TamR cell conditioned medium 
to promote vessel growth compared to w&5 control media. 
5.3.2 TAMR, but not MCF7 Conditioned Media Promotes Proliferation 
and Tubule Formation in the Rat Aortic Ring Assay 
The rat aortic ring assay was used to determine whether alterations in 
angiogenesis seen in vitro in response to conditioned media from tamoxifen 
resistant breast cancer cell models could be reproduced in a more complex 
biological system. These assays involve culture of dissected sections of the 
descending thoracic aorta from juvenile rats (Burbridge et al., 2001) in a 
Matrigel bed and monitoring tubule outgrowth in response to specific stimuli. 
One benefit of using ex vivo tissue as opposed to primary endothelial cells in 
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vitro is that it will allow observation of the effect the surrounding cells have on 
the process of angiogenesis. However, this can also complicate experiments as 
a plethora of factors produced by other cells in the tissue, for example 
fibroblasts, may produce factors that influence the growth of endothelial cells 
through signalling that may not involve VEGF. However, the use of 
experimental medium (w&5) and MCF7wt conditioned media was able to control 
for this to a large extent. 
Endothelial cells in this model represent established vasculature better in that 
they are not in a high proliferative state as cells in culture for several passages 
would be. However, the initiation of the angiogenic response may well be 
influenced in response to the injury arising as part of the dissection procedure 
(Nicosia et al., 2011) which is less representative of angiogenesis in cancer. 
Nevertheless it remains a popular, and well validated, model for assessing 
angiogenesis and factors that affect angiogenesis (Feng et al., 2012; 
Kayashima et al., 2012).  
Our data (Figure 5.2) illustrated a significant increase in endothelial cell 
outgrowth from aortic tissue and the subsequent formation of endothelial 
tubules following exposure to conditioned media from TamR cells versus 
MCF7wt cells. Previous studies have shown that stimulation of rat aortic tissue 
with growth factors such as VEGF results in an increased proliferative 
response, even after endothelial cells have begun to senesce and become 
reabsorbed (Nicosia et al., 1997) . Interestingly, MCF7wt conditioned media 
treatment of aortic ring sections resulted in both a reduced proliferation of 
endothelial cells and also an increased proliferation of non-endothelial cells, 
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determined to be fibroblasts based on their morphology and incapability to form 
tubules. 
Given that conditioned media from TamR cell lines possess elevated VEGF 
concentrations we hypothesise that this contributed to elevated endothelial cell 
proliferation. One aspect of this assay that was not investigated due to time 
limitations, but should be done in the future, is to perform the assay in the 
presence of the specific VEGFR2 inhibitor, ZM323881, in order to validate 
VEGF as the stimulating ligand in this system. Furthermore, to illustrate that the 
VEGF effecting the change is from the conditioned media and not surrounding 
stromal cells, cells from which conditioned media is collected could be pre-
treated with inhibitors that reduce VEGF production (e.g. Src kinase inhibitor), 
before the media is collected for use on tissue in this system.  
Although tubule formation is expected to be specific to the endothelial cells, this 
could additionally be confirmed in these types of assays by subsequently 
staining for the endothelial specific marker, CD31, or using FITC labelled GSL-
1, another endothelial cells specific cell marker.   
5.3.3 TAMR Xenograft Tissue is More Highly Vascularised than 
MCF7wt Xenograft Tissue 
Murine models are routinely used in the study of cancer development and 
treatment. Severely immunocompromised mice will readily accept xenografts 
from human cells without rejection (Morton et al., 2007). These models can then 
be used to examine the development of tumours, their metastatic and invasive 
properties as well as the response to treatment. Positive attributes of xenograft 
150 
 
studies include the ease of model development and comparatively quick 
turnaround from grafting to therapeutic response as well as the fact that the 
tumours that are developed are human in origin and so are better 
representatives of human tumours in situ than those from studies using 
alternative species’ tumours i.e. genetically engineered mouse models.  
CD31 was initially identified on endothelial cells and platelets (van Mourik et al., 
1985) where it was shown to act as a cell adhesion molecule and also as a 
promoter of intracellular signalling cascades that may function in the regulation 
of angiogenesis. (Liu et al., 2012; Newman, 1999). Endothelial cell lines such as 
HUVEC have been shown to express CD31 at a high density both in vitro and in 
vivo at a level of approximately 1x106 per endothelial cell (Newman, 1999). 
When grown as monolayers, endothelial cells express CD31 along the borders 
of the cell at cell-cell junctions (McCarthy et al., 1991). CD31 is also routinely 
used in the identification of endothelial cells in clinical tissue (Arnold et al., 
2012; Croix et al., 2000; Hull et al., 1996) and thus represented an appropriate 
marker to identify vascularisation in these xenografts. Importantly, the antibody 
used recognised both human and mouse antigens and so could detect murine 
vascularisation of the human xenograft tissue. 
Our data illustrate that CD31 staining was highest in TamR xenografts, 
revealing a greater number of both small and large vessel structures. 
Previously, studies that examined the effect of VEGF inhibition in xenograft 
models of breast cancer cells have demonstrated that reduction of VEGF 
signalling leads to a reduced tumour microvessel density (Roland et al., 2009). 
Therefore, conversely, we propose that elevated VEGF produced by TamR 
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cells leads to an increase in vascularisation of tissue when compared to 
MCF7wt xenografts. Other growth factors and signalling molecules could be 
mediating this change in xenografts so verification of this proposition could be 
carried out by inhibition of VEGF in TamR cell xenografts. 
5.4 Chapter Summary 
In this chapter, we have explored whether the in vitro pro-angiogenic properties 
of conditioned media from endocrine-resistant breast cancer cells observed 
translated into pro-angiogenic effects in vivo. Using a number of techniques, we 
have shown that: 
- Despite the poor viability associated with the chick chorioallantoic assay there 
was a suggestion that TamR conditioned media promoted vasculature 
development versus MCF7wt media.  
- TamR cell conditioned media increased the formation of endothelial cell 
tubules surrounding rat aortic ring sections grown on Matrigel versus MCF7wt 
cells 
- Whilst both TamR and MCF7wt xenograft tissue stained positive for the 
endothelial marker, CD31, the extent of staining was significantly greater in 
TamR sections when compared to MCF7wt tissues.  
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Chapter 6: General Discussion 
6.1 Summary of Data 
Our results demonstrate that Src-dependant upregulation of VEGF in TamR cell 
promotes in vitro and ex vivo angiogenic responses in endothelial cells. 
Furthermore xenografts from TamR cells appear highly vascularised compared 
to MCF7wt cell xenograft tissue. 
6.2 Discussion 
Incidence rates of breast cancer continue to rise with time (Office for National 
Statistics, 2008). These data are as a result of increased screening programs 
coupled with improvements in treatment regimens (Glass et al., 2007). 
However, although mortality rates are decreasing it remains the most common 
cause of death in women after lung cancer. 
Breast cancer is a heterogeneous disease that comprises as a number of 
clinical and histological subtypes. Selection of therapy following tumour excision 
is usually determined based on the presence of ER and PR receptors and the 
expression level of the HER2 receptor. For ER positive cancers, treatment 
strategies are employed that target the binding or production of oestrogen. 
These treatments include selective oestrogen receptor modulators (such as 
tamoxifen) which bind ER and antagonise its function leading to reduction in cell 
proliferation (Riggs et al., 2003). The advent of aromatase inhibitors has largely 
replaced the use of tamoxifen in postmenopausal women; however, treatment 
with ER receptor antagonists is still the primary choice in receptor positive pre-
menopausal women.  
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Despite the proven benefits of tamoxifen and other ER antagonists, their clinical 
use is limited by resistance which occurs in two-thirds of ER+ tumours initially 
respond to therapy (Dorssers et al., 2001). Acquired tamoxifen resistance is 
associated with tumour spread clinically and a poor prognosis (Ring et al., 
2004). In vitro data has also shown that breast cancer cells that become 
endocrine-resistant also display a more aggressive and invasive phenotype 
(Hiscox et al., 2004), (mediated in part through the increased expression and/or 
activation of intracellular pro-invasive kinases including Src-kinase and focal adhesion 
kinase) (Hiscox et al., 2007; Hiscox et al., 2006b). Acquired resistance may also 
augment the capacity of breast cancer cells to interact with other elements 
(cells and proteins) in the tumour microenvironment: for example, 
overexpression of c-Met accompanies fulvestrant resistance in MCF7wt cells 
which subsequently renders these cells more sensitive to stromally produced 
HGF (Hiscox et al., 2006a). Despite these data suggesting interplay between 
breast cancer cells and other cell types in the tumour microenvironment in the 
context of endocrine resistance, there is little data regarding whether acquisition 
resistance has any bearing on the angiogenic capacity of breast cancer cells 
that would further favour both tumour progression and spread in vivo. Thus, this 
formed the aim of this PhD thesis.  
The development of blood vessels surrounding tumours can be influenced by 
paracrine signalling from tumour cells and the surrounding stroma (Kerbel, 
2008). On acquisition of tamoxifen resistance, key signalling pathways 
governing tumour cell growth and survival are deregulated, which alters the 
development of the tumour (Ring et al., 2004; Shou et al., 2004). However, 
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some of these pathways also regulate angiogenic signalling (Koduri et al., 2006; 
Tabernero, 2007). We hypothesised that such deregulation may also play a role 
in the development of a proangiogenic phenotype in anti-oestrogen resistant 
breast cancer cells. The clinical implications of this are that increased 
angiogenic signalling could sustain resistant tumour development and spread 
as new vasculature promotes growth and an increased risk of further 
metastasis.  
Initial results demonstrated that the expression of genes with pro-angiogenic 
ontology is increased in our in vitro cell lines modelling tamoxifen (TamR), 
fulvestrant (FasR) and aromatase inhibitor (MCF7-X) resistance when 
compared to endocrine responsive MCF7wt cells. Gross gene deregulation was 
observed in the microarray profiles produced from the resistant models vs. 
MCF7wt, however, the gene signature of this deregulation was not consistent 
between the three resistant cell lines. This may be as a result of the different 
mechanisms by which these three agents (tamoxifen, fulvestrant and oestrogen 
withdrawal) act and the mechanisms by which resistance develops. One 
consideration in this context is that of the ER, the expression of which is retained in 
TamR and MCF7-X cells but is lost in FasR cells. To select out which genes 
represented potential candidates for further exploration, we looked for genes that fit a 
certain set of criteria. Our criteria demanded that these genes were; (i) positively 
upregulated and pro-angiogenic, to allow easy manipulation of their function by 
downregulation using inhibitor studies; (ii) be well established in the literature, to 
provide information on their mechanism and regulation; (iii) targetable, through the 
presence of commercially available inhibitors, to allow easy manipulation of signalling; 
(iv) given our previous knowledge of Src and FAK deregulation in endocrine resistant 
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cell models, implicated as downstream targets of these kinases. Genes that were 
significantly upregulated in resistant cells that fit these criteria were the growth factor, 
VEGF, and the cytokine IL-8. 
To confirm these factors played a role in endothelial cell proliferation, we treated 
HUVEC and HECV cells with VEGF and IL-8 ligand. IL-8, however, failed to 
produce a proliferative response in either of our endothelial cell models despite 
having detected both CXCR1 and CXCR2 receptors in these cells. We 
hypothesise that IL-8 may function in cooperation with co-factor molecules 
including other chemokines, such as IL-6, that bind CXC receptors (Acosta et 
al., 2008). In support of this, our experiments in which we supplemented serum-
containing media with IL-8 and observed a small but significant increase in 
endothelial cell proliferation pointing to the presence of other factors in serum 
which might co-operate with IL-8 to produce endothelial cell growth. Other 
studies have shown that IL-8 can directly stimulate the proliferation of HUVECs 
in vitro (Li et al., 2003) although these studies used whole serum and 
supplemented media in addition to IL-8 ligand which may explain the 
differences with our data.  
VEGF, in contrast to IL-8, promoted endothelial cell proliferation and was taken 
forward for further investigation. VEGF is a key potentiator of angiogenesis and 
elevated expression is directly tied to increased proliferative and migratory 
response in endothelial cells (Hoeben et al., 2004). VEGF was produced by all our 
resistant cell models but was highest in TamR conditioned media which also induced a 
significant response in promoting endothelial cell growth. In contrast, conditioned 
media from FasR and MCF7-X cells did not have a significant proliferative effect on 
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endothelial cells. This is despite findings that indicated their VEGF profile at a protein 
level was significantly increased over control media. However, array analysis of these 
two cell lines illustrated that they also possessed elevated mRNA expression of a 
number of anti-angiogenic agents such as thrombospondin-1, which could potentially 
function to reduce the pro-angiogenic effects of VEGF (Lawler, 2002). As cell 
proliferation is required for the development of new vasculature, only TamR 
cells were used in further investigations.  
Validation of increased TamR VEGF expression by mRNA and protein analysis 
confirmed data from the only previous study to examine VEGF concentration in 
a model of tamoxifen resistance (Kim et al., 2009). Although this group derived 
their tamoxifen resistant MCF7wt cell line using methodology published by our 
group (Knowlden et al., 2003) they have not published a characterisation of these 
cells. We cannot therefore determine whether their TamR cell line has the same 
characteristics as ours which are known to overexpress EGFR, Src and FAK and so 
the mechanisms underlying VEGF production in this model may be different. We 
examined the effect of removing VEGF signalling by inhibition of the VEGFR2 
receptor. This is the main effector of VEGF signalling and the majority of its 
actions result in angiogenic responses (Ferrara et al., 2003). Inhibition of 
signalling through this receptor using the small molecule inhibitor ZM323881 
reduced downstream signalling through MAPK and Akt as well as reducing 
TamR induced proliferation of endothelial cells. 
To examine the mechanism by which VEGF expression is increased in TamR 
cells we initially explored the role of HIF1-α, which is known to be a key 
regulator of pro-angiogenic signalling (Ke et al., 2006). VEGF is known to be 
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upregulated in some ovarian cancers and its expression correlates with the 
expression of HIF1α (Wong et al., 2003). In breast cancer, HIF1α has been 
shown to be increased in poorly differentiated lesions and in more advanced 
stages of breast cancer. This also correlated with increased VEGF expression 
(Bos et al., 2001). Clinically, increased HIF1α has been suggested as a 
predictive factor for endocrine resistance in ER+ cancers (Generali et al., 2006). 
In our study, however, no difference was seen in HIF1α expression between our 
MCF7wt and TamR groups. Additional work using cobalt chloride to mimic the 
effects of hypoxia and thus to increase HIF1α, and HIF1α regulated proteins, 
found that although CoCl2 increased HIF1α activation this did not result in 
increased VEGF expression nor did conditioned media from CoCl2 treated 
TamR cells result in increased proliferative responses in endothelial cells (data 
not shown).  
Since no significant differences in HIF1α expression or activity between our 
endocrine-sensitive and tamoxifen resistant cell lines were found, we next 
explored the role of ER given that previous work has illustrated that VEGF 
expression in clinical tissue from breast cancer patients is correlated with ER 
status (Adams et al., 2000).  
Despite this clinical data suggesting a link between ER and VEGF, the effect of 
ER modulation on VEGF expression in vitro are not clear. Some studies have 
shown that MCF7wt cells, treated with tamoxifen, demonstrated a reduced 
expression of VEGF mRNA whilst stimulation of the ER with oestradiol resulted 
in increased VEGF expression (Lee et al., 2004). However, other studies in 
contrast suggest that tamoxifen treatment of endocrine-sensitive cell lines in 
158 
 
vitro increases the expression of VEGF (Bogin et al., 2002; Ruohola et al., 
1999). Our own analysis revealed no significant change in VEGF expression 
when MCF7wt cells were treated with oestradiol, tamoxifen or fulvestrant. 
Furthermore, VEGF production in resistant cell models did not correlate with ER 
status. 
Having found that neither HIF1α nor ER, function in the deregulation of VEGF, 
we next examined the role of Src kinase, known to be upregulated in acquired 
tamoxifen resistance (Hiscox et al., 2006b) and to regulate expression of VEGF 
(Chou et al., 2010; Summy et al., 2005), although this mechanism is not fully 
understood. Our data confirmed that TamR cells have increased Src activity 
correlating with an increased VEGF expression. Subsequently we demonstrated 
that inhibition of Src reduced VEGF expression in TamR cells and also 
attenuated the ability of TamR conditioned media to induce endothelial cell 
proliferation. 
The capacity of TamR cells to induce angiogenic behaviour in endothelial cell 
models was demonstrated by increases in proliferation, migration and formation 
of tubules in response to TamR conditioned media. Vascular development in 
vivo requires all three processes to produce new functional vessels 
(Chrzanowska-Wodnicka et al., 2008). Additionally the integrity of tight junctions 
between endothelial cells can influence the process of angiogenesis. The 
degradation of these junctions allows endothelial cells to move outwards from 
the parent vessel towards a pro-angiogenic signal such as that from tumour 
cells. We made use of electric cell-substrate impedance sensing (ECIS) assays 
to assess the effect of conditioned media on the transendothelial resistance 
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(TER) of the endothelial cell line, HECVs. Despite high variation seen between 
experiments, we found encouraging data indicating that TamR conditioned 
media decreased TER to a greater extent than MCF7wt conditioned media. 
Reductions in TER can be suggestive of increased vascular permeability or as a 
reduction in tight junction integrity and therefore further experimentation will be 
required to determine which of these processes is responsible for the results 
seen (Kröll et al., 2009). 
To move our in vitro work towards an in vivo system, we performed rat aortic 
ring assays. These data illustrated that conditioned media from TamR cells 
induced the proliferation of ex vivo endothelial cells to a greater extent than 
MCF7wt conditioned media. We subsequently attempted to perform further in 
vivo work using the chick chorioallantoic membrane assay. Although these were 
disappointingly without success (due to a lack of viable embryos) one 
experiment did appear to show vessel growth in response to TamR conditioned 
media but not to w&5 control media.  
Xenografts of cell lines transplanted from in vitro culture environments into 
nude-mice provide valuable insight into how tumours similar to these cell lines 
will behave in a more complex system (Clarke, 1996). For our purposes, we 
sought to examine how these cell lines would influence the surrounding tissue 
in terms of development of vasculature. Our data demonstrated increased 
presence of endothelial cell staining in TamR cell xenografts when compared to 
MCF7wt xenografts. This endothelial cell presence is representative of 
increased vascularisation of these xenografts. It has already been established 
that VEGF concentration is directly correlated with microvessel density in breast 
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cancer tumours in the clinic (Thielemann et al., 2008) but whether increased 
microvessel density represents a useful prognostic factor remains to be 
elucidated (Duarte et al., 2007; Nakamura et al., 2003).It is important to note the 
limitations of xenograft studies. In our experiments, the MCF7wt xenograft 
group were implanted with cells that had been supplemented with oestradiol as 
previous experimentation has illustrated that exogenous supplementation with 
this ligand is necessary for the xenograft to survive in the host animal. Removal 
of the oestradiol supplementation from MCF7wt xenografts results in tumour 
regression illustrating their dependence on oestrogenic signalling (VanWeelden 
et al., 1998). Oestradiol supplementation of TamR cells has no effect on their 
growth and is routinely excluded from xenograft procedures.  
As an aside to our main project goals, we initially hypothesised that the 
presence of elevated growth factor signalling through angiogenic pathways may 
also lead to endocrine insensitivity in breast cancer cells through co-opting of 
receptor pathways such as VEGFR2. In addition, breast cancer cells that are 
positive for the VEGFR2 receptor have previously been shown to be directly 
stimulated by VEGF, resulting in increased proliferation and migration 
responses (Liang et al., 2006; Mercurio et al., 2005). Our data, however, 
suggest that our MCF7wt and TamRs are negative for these receptors and 
direct stimulation with VEGF ligand did not produce a proliferative response.  
Angiogenesis is an important process in breast cancer but may be of greater 
importance in breast cancers that have acquired tamoxifen resistance as they 
may show further deregulation of proangiogenic factors including VEGF. Such 
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data suggest that targeted therapies that primarily inhibit VEGF may be useful 
in this context.   
Bevacizumab is a recombinant humanised monoclonal antibody that directly 
binds VEGF and prevents its subsequent binding to VEGF receptors (Ferrara et 
al., 2004). In the RiBBOn-1 (Regimens in Bevicizumab for Breast Oncology-1) 
and RiBBOn-2 phase III trials patients received chemotherapy and 
bevacizumab (or placebo) with progression-free survival (PFS) being assessed 
as the primary end-point (Brufsky et al., 2009; Robert et al., 2011). Both studies 
demonstrated a significant increase in PFS when patients were receiving both 
chemotherapy and bevacizumab. RiBBOn-2 revealed a trend towards increased 
overall response rate when bevacizumab was combined with chemotherapy, 
however, neither trial found significant differences in overall survival with the 
addition of bevacizumab.  
Bevacizumab therapy is also associated with a number of adverse effects 
including severe hypertension, heart failure and a perforations of soft tissues in 
the nose, stomach and bowel (Tanne, 2011). As a result its indication for use in 
breast cancer was revoked in November 2011 by the Federal Drug 
Administration (Brufsky et al., 2011; Pivot et al., 2011; Smith et al., 2011).  
Small molecule inhibitors of receptor tyrosine kinases that inhibit receptors such 
as VEGFR2 have had some pre-clinical success. Sunitinib (Sutent) binds to 
VEGFR2 as well as PDDFR-β, FLT3 and c-Kit. It has demonstrated anti-tumour 
activity in preclinical models of breast cancer as a single agent and in 
combination therapy with chemotherapeutics such as docetaxel (Abrams et al., 
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2003; Murray et al., 2003). However, it did not demonstrate significant gains in 
progression free survival in the phase III clinical trials for use of the drug in the 
treatment of advanced HER-2 negative breast cancer or as a combination 
therapy in conjunction with capecitabine (Barrios et al., 2010). Sorafenib 
(Nexavar) has had more success in the clinic with one phase IIb trial improves 
progression free survival in metastatic breast cancer when combined with 
capecitabine or paclitaxel (Gradishar, 2010).  
The current view of these therapies is that they can give increased progression 
free survival and response rate when used in conjunction with a chemotherapy 
regimen but do not produce an increase in overall survival when compared to 
chemotherapy alone. Difficulties in treatment of breast cancer using anti-
angiogenic monotherapy appear to include the identification of patient 
subgroups that will benefit and being able to administer a high enough dose to 
effect a positive change in tumour growth without the inset of severe side 
effects due to the relatively poor therapeutic index of current therapies (Mackey 
et al., 2012). We suggest then, that in lieu of targeting VEGF directly, inhibition 
of upstream regulators of VEGF such as Src kinase may be beneficial in 
treating tumours which possess increased vascularisation and VEGF 
concentrations. In addition, targeting Src may also reduce further adverse 
aspects of resistance such as migration and invasion (Hiscox et al., 2006b). 
Despite the numerous studies investigating anti-angiogenic therapy in breast 
cancer, it has not been evaluated for use in tamoxifen-resistant cancers, 
however, data here present a rationale for this based on the proangiogenic 
prolife of tamoxifen resistant cancer cells.  
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One phase I/II trial in lung cancer profiling Src and EGFR inhibition illustrated 
significant reductions in plasma VEGF which correlated with disease control 
(Haura et al., 2010). In breast, two studies that inhibited either VEGF, using 
bevacizumab, or Src, using the small molecule inhibitor dasatinib, found that 
both methods resulted in increased VEGFR2 expression which may result as a 
compensatory mechanism in the event of reductions in VEGF ligand (Denduluri 
et al., 2008; Strauss et al., 2009). Data suggests that Src inhibition alters VEGF 
expression in clinical breast cancer, however, data from clinical trials using Src-
inhibition as a monotherapy or in conjunction with anti-endocrine agents is 
necessary to provide a clearer picture on its role as a novel therapy. In addition 
to its use as a first line therapy, we hypothesise that combination therapy using 
Src kinase inhibitors and endocrine agents may offset the development of a pro-
angiogenic phenotype on acquisition of endocrine resistance or even prevent 
resistance from developing (Hiscox et al., 2009).  
Our data demonstrate that acquired tamoxifen resistance in breast cancer 
confers a proangiogenic phenotype to cells. Underlying this appears to be a 
Src-dependant increase in VEGF which promotes VEGFR2 mediated 
endothelial cell growth. Although anti-angiogenic therapies have had low 
success in the clinical treatment of breast cancers, these have not yet been 
primarily directed to the treatment of endocrine-resistant tumours in which the 
tumours may rely more heavily on signalling through angiogenic pathways. This 
is excluding a handful of phase I and II trials which reported no significant 
improvements with treatment with bevacizumab. That said, bevacizumab, 
although previously popular is not the only anti-angiogenic agent. There 
164 
 
remains the possibility that treatment with other small molecule inhibitors 
targeting angiogenic ligands may prove more beneficial.  
6.2 Future Perspectives 
In this work, we have examined the role played by VEGF in the altered 
angiogenic signalling observed in tamoxifen resistant breast cancer models. 
From the microarray analysis carried out at the beginning of this project, several 
other candidate factors were found to be overexpressed in TamR cells 
compared to MCF7wt cells. These factors included FGF and TGFβ1 which have 
previously been implicated in pro-angiogenic signalling (Cross et al., 2001; 
Pepper, 1997). The relevance of such factors could be tested using the same 
methodology as that used for VEGF analysis and may illustrate how altered 
angiogenic signalling is a multifactorial process and not wholly under the control 
of the VEGF/VEGFR2 axis in tamoxifen resistant cells.  
Further expansion of breast cell lines used to include those that model different 
breast cancer subtypes would be useful in assessing how angiogenic signalling 
differs between them and may identify particular subtypes that would be most 
sensitive to anti-angiogenic therapy. Currently, our group is developing 
tamoxifen resistant T47D cells which would be useful in corroborating data from 
tamoxifen resistant MCF7wt cells as they both represent ER+ breast cancers. 
We also have access to TamR cells that have been cultured in the presence of 
tamoxifen for longer periods of time (2 years+) which may be more 
representative of the clinical treatment time. 
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Although we obtained some encouraging data from our ex vivo assays the use 
of in vivo functional assays to support our in vitro data in more complex systems 
would be of great benefit. In vivo assays could include xenograft implantation of 
TamR cells in nude mice ± antiangiogenic therapy or Src inhibitors. We also 
intend to extend our xenograft study to encompass FasR xenograft models and 
hypothesise that as a result of reduced VEGF expression, we may see reduced 
microvessel density in these samples. 
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